FONAR (FONR) 10-K 30 Sep 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2019	Sep. 13, 2019	Dec. 31, 2018
Entity Registrant Name	FONAR CORP
Entity Central Index Key	0000355019
Document Type	10-K
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity File Number	0-10248
Is Entity Incorporation State Country Code	DE
Is Entity a Well-known Seasoned Issuer?	Yes
Is Entity a Voluntary Filer?	No
Is Entity Interactive Data Current	Yes
Is Entity's Reporting Status Current?	Yes
Is Entity a Small Business	false
Entity Filer Category	Accelerated Filer
Is Entity an Emerging Growth Company	false
Is Entity a Shell Company	false
Entity Public Float			$ 130,000,000
Common Shares
Entity Common Stock, Shares Outstanding		6,447,463
Class A Non-Voting Preferred Stock
Entity Common Stock, Shares Outstanding		313,438
Class C Common Stock
Entity Common Stock, Shares Outstanding		382,513
Class B Members
Entity Common Stock, Shares Outstanding		146

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Current Assets:
Cash and cash equivalents	$ 13,882,013	$ 19,633,742
Short term investments	15,094,816
Accounts receivable - net	3,736,662	3,813,576
Medical receivables -net	15,728,935	13,350,772
Management and other fees receivable -net	25,709,489	21,863,431
Management and other fees receivable - related medical practices -net	6,500,614	5,535,096
Costs and estimated earnings in excess of billings on uncompleted contracts	525,110	86,638
Inventories	1,798,166	1,431,380
Income taxes receivable - current	600,000
Prepaid expenses and other current assets	1,512,917	1,349,907
Total Current Assets	85,088,722	67,064,542
Income taxes receivable	600,000	1,200,000
Deferred income tax asset	20,937,747	22,689,011
Property and equipment - net	16,985,617	16,492,278
Goodwill	3,985,397	3,985,397
Other intangible assets - net	4,755,675	5,601,656
Other Assets	1,207,052	1,278,061
Total Assets	133,560,210	118,310,945
Current Liabilities:
Current portion of long-term debt and capital leases	40,530	38,332
Accounts payable	1,861,227	1,300,250
Other current liabilities	7,577,416	8,177,995
Unearned revenue on service contracts	3,812,115	4,191,930
Customer deposits	798,651	858,195
Total Current Liabilities	14,089,939	14,566,702
Long-Term Liabilities:
Deferred Income Tax Liability	243,267	239,011
Due to related party medical practices	92,663	227,543
Long-term debt and capital leases, less current portion	273,112	306,035
Other Liabilities	749,126	737,183
Total Long-Term Liabilities	1,358,168	1,509,772
Total Liabilities	15,448,107	16,076,474
STOCKHOLDERS' EQUITY:
Paid-in capital in excess of par value	181,086,517	179,131,780
Accumulated deficit	(64,455,456)	(79,772,587)
Notes receivable from employee stockholders		(9,213)
Treasury stock, at cost - 11,643 shares of common stock at June 30, 2019 and 2018	(675,390)	(675,390)
Total Fonar Corporation Stockholder Equity	115,956,378	98,675,289
Noncontrolling interests	2,155,725	3,559,182
Total Stockholders' Equity	118,112,103	102,234,471
Total Liabilities and Stockholders' Equity	133,560,210	118,310,945
Class A Non-Voting Preferred Stock
STOCKHOLDERS' EQUITY:
Preferred Stock Value	31	31
Preferred Stock
STOCKHOLDERS' EQUITY:
Preferred Stock Value
Class B Members
STOCKHOLDERS' EQUITY:
Common Stock Value
Common Shares
STOCKHOLDERS' EQUITY:
Common Stock Value	638	630
Class C Common Stock
STOCKHOLDERS' EQUITY:
Common Stock Value	$ 38	$ 38

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Jun. 30, 2018
Class A Non-Voting Preferred Stock
Preferred Stock, Par Value	$ 0.0001	$ 0.0001
Preferred Stock, Authorized	453,000	453,000
Preferred Stock, Issued	313,438	313,438
Preferred Stock, Outstanding	313,438	313,438
Preferred Stock
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Authorized	567,000	567,000
Preferred Stock, Issued
Preferred Stock, Outstanding
Common Shares
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Authorized	8,500,000	8,500,000
Common Stock, Issued	6,369,125	6,299,154
Common Stock, Outstanding	6,357,482	6,287,511
Class B Members
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Authorized	227,000	227,000
Common Stock, Issued	146	146
Common Stock, Outstanding	146	146
Class C Common Stock
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Authorized	567,000	567,000
Common Stock, Issued	382,513	382,513
Common Stock, Outstanding	382,513	382,513

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
REVENUES
Patient fee revenue, net of contractual allowances and discounts	$ 24,207,536	$ 39,165,413	$ 36,400,600
Provision for bad debts for patient fee		(17,896,528)	(16,171,434)
Patient fee revenue - net	24,207,536	21,268,885	20,229,166
Product sales - net	1,751,221	602,541	1,572,148
Service and repair fees - net	8,152,173	9,124,728	9,537,040
Service and repair fees - related parties - net	110,000	110,000	110,000
Management and other fees - net	43,617,093	41,422,958	38,361,514
Management and other fees - related party medical practices - net	9,354,864	8,986,882	8,226,718
Total Revenues - Net	87,192,887	81,515,994	78,036,586
COSTS AND EXPENSES
Costs related to product sales	778,734	751,221	931,501
Costs related to service and repair fees	3,009,097	3,212,527	2,996,736
Costs related to service and repair fees -related parties	40,603	38,728	34,564
Costs related to patient fee revenue	10,789,308	10,256,951	8,987,673
Costs related to management and other fees	23,419,796	22,778,202	20,828,581
Costs related to management and other fees - related medical practices	5,947,055	4,913,141	4,273,370
Research and development	1,812,347	1,755,747	1,480,670
Selling, general and administrative is inclusive of compensatory element of stock issuances	19,261,755	18,125,266	19,407,411
Total Costs and Expenses	65,058,695	61,831,783	58,940,506
INCOME
Income from Operations	22,134,192	19,684,211	19,096,080
Other Income and (Expenses):
Interest expense	(98,636)	(160,074)	28,299
Investment income	482,573	262,569	193,141
Other income (expense)- net	1,065	(4,271)	(1,156)
Income before (provision) benefit for income taxes and noncontrolling interests	22,519,194	19,782,435	19,316,364
(Provision) benefit for income taxes	2,005,520	(5,669,750)	(4,362,434)
Net Income	20,513,674	25,452,185	23,678,798
Net Income - Noncontrolling Interests	(5,196,543)	(4,221,383)	(4,058,177)
Net Income - Attributable to FONAR	15,317,131	21,230,802	19,620,621
Common Shares
Other Income and (Expenses):
Net Income - Attributable to FONAR	$ 14,366,798	$ 19,899,823	$ 18,390,586
Basic Net Income Per Common Share	$ 2.26	$ 3.16	$ 2.98
Diluted Net Income Per Common Share	$ 2.22	$ 3.1	$ 2.92
Weighted Average Basic Shares Outstanding - Common Stockholders	6,354,103	6,287,510	6,161,599
Weighted Average Diluted Shares Outstanding - Common Stockholders	6,481,607	6,415,014	6,289,103
Class A Non Voting Preferred Stock
Other Income and (Expenses):
Net Income - Attributable to FONAR	$ 708,302	$ 992,005	$ 916,769
Class C Common Stock
Other Income and (Expenses):
Net Income - Attributable to FONAR	$ 242,031	$ 338,974	$ 313,266
Basic Net Income Per Common Share	$ 0.63	$ 0.89	$ 0.82
Diluted Net Income Per Common Share	$ 0.63	$ 0.89	$ 0.82
Weighted Average Basic Shares Outstanding - Common Stockholders	382,513	382,513	382,513
Weighted Average Diluted Shares Outstanding - Common Stockholders	382,513	382,513	382,513

Statements of Operations (Paren

Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
compensatory element of stock issuances	$ 1,990,380	$ 1,954,744	$ 2,397,276

Shareholders Equity and Compreh

Shareholders Equity and Comprehensive Income - USD ($)	Common Shares	Class A Non Voting Preferred Stock	Class C Common Stock	Paid-in Capital in Excess of Par Value	Accumulated Deficit	Notes Receivable from Employee Stockholders	Treasury Stock	Noncontrolling Interests	Total
Balance - Beginning, Value at Jun. 30, 2016	$ 607	$ 31	$ 38	$ 173,702,335	$ (120,624,010)	$ (23,879)	$ (675,390)	$ 8,396,575	$ 60,776,307
Balance - Beginning, Shares at Jun. 30, 2016	6,051,166
Net Income					$ 19,620,621			$ 4,058,177	$ 23,678,798
Stock issued to employees under stock bonus plans, Value	$ 19			$ 4,636,559					$ 4,636,578
Stock issued to employees under stock bonus plans, Shares	193,221
Payments on notes receivable from employee stockholders						$ 7,333			$ 7,333
Issuance of stock for acquistion, Value	$ 4			$ 791,206					$ 791,210
Issuance of stock for acquistion, Shares	42,884
Stock option exercised, Value				$ 1,680					$ 1,680
Stock option exercised, Shares	240
Distributions to noncontrolling interests								$ (6,981,953)	$ (6,981,953)
Balance - Ending, Value at Jun. 30, 2017	$ 630	$ 31	$ 38	$ 179,131,780	$ (101,003,389)	$ (16,546)	$ (675,390)	$ 5,472,799	$ 82,909,953
Balance - Ending, Shares at Jun. 30, 2017	6,287,511
Net Income					$ 21,230,802			$ 4,221,383	$ 25,452,185
Stock issued to employees under stock bonus plans, Value
Stock issued to employees under stock bonus plans, Shares
Payments on notes receivable from employee stockholders						$ 7,333			$ 7,333
Issuance of stock for acquistion, Value
Issuance of stock for acquistion, Shares
Stock option exercised, Value
Stock option exercised, Shares
Distributions to noncontrolling interests								$ (6,135,000)	$ (6,135,000)
Balance - Ending, Value at Jun. 30, 2018	$ 630	$ 31	$ 38	$ 179,131,780	$ (79,772,587)	$ (9,213)	$ (675,390)	$ 3,559,182	$ 102,234,471
Balance - Ending, Shares at Jun. 30, 2018	6,287,511
Net Income					$ 15,317,131			$ 5,196,543	$ 20,513,674
Stock issued to employees under stock bonus plans, Value	$ 8			$ 1,954,737					$ 1,954,745
Stock issued to employees under stock bonus plans, Shares	69,971
Payments on notes receivable from employee stockholders						$ 9,213			$ 9,213
Issuance of stock for acquistion, Value
Issuance of stock for acquistion, Shares
Stock option exercised, Value
Stock option exercised, Shares
Distributions to noncontrolling interests								$ (6,600,000)	$ (6,600,000)
Balance - Ending, Value at Jun. 30, 2019	$ 638	$ 31	$ 38	$ 181,086,517	$ (64,455,456)		$ (675,390)	$ 2,155,725	$ 118,112,103
Balance - Ending, Shares at Jun. 30, 2019	6,357,482

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income	$ 20,513,674	$ 25,452,185	$ 23,678,798
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,836,491	3,899,851	3,533,564
(Credit) Provision for bad debts	(978,730)	(614,680)	477,577
Deferred income tax benefit	1,755,520	(4,919,750)	(4,969,669)
Income tax receivable		(1,200,000)
Compensatory element of stock issuances			2,397,276
Stock issued for costs and expenses	$ 1,954,745		$ 2,239,302
Stock option exercised			1,680
(Increase) decrease in operating assets, net:
Accounts, medical and management fee receivables	$ (6,134,095)	$ (4,328,239)	$ (5,899,611)
Notes receivable	(12,689)	(894,665)	11,511
Costs and estimated earnings in excess of Billings on uncompleted contracts	(438,472)	649,423	(736,061)
Inventories	(366,786)	192,882	450,038
Prepaid expenses and other current assets	(79,641)	(1,553)	(513,507)
Other assets	329	15,008	254,721
Increase (decrease) in operating liabilities, net:
Accounts payable	560,977	(122,967)	168,733
Other current liabilities	(980,394)	525,113	(3,660,895)
Customer advances	(59,544)	70,311	(410,855)
Billings in excess of costs and estimated earnings on uncompleted contracts			(206,623)
Other Liabilities	11,943	16,404	8,783
Due to related party medical practices	(134,880)		(17,498)
NET CASH PROVIDED BY OPERATING ACTIVITIES	19,448,448	18,739,323	16,807,264
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(3,355,456)	(2,777,948)	(2,851,158)
Short term investment	(15,094,816)
Cost of acquisition		(58,274)	(1,312,769)
Cost of patents	(128,393)	(108,829)	(155,156)
NET CASH USED IN INVESTING ACTIVITIES	(18,578,665)	(2,945,051)	(4,319,083)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of borrowings and capital lease obligations	(30,725)	(172,484)	(3,990,078)
Repayment of notes receivable from employee stockholders	9,213	7,333	7,333
Distributions to noncontrolling interests	(6,600,000)	(6,135,000)	(6,981,953)
Proceeds received from acquisition -net			87,829
NET CASH USED IN FINANCING ACTIVITIES	(6,621,512)	(6,300,151)	(10,876,869)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(5,751,729)	9,494,121	1,611,312
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	19,633,742	10,139,621	8,528,309
CASH AND CASH EQUIVALENTS - END OF YEAR	$ 13,882,013	$ 19,633,742	$ 10,139,621

NOTE 1 - DESCRIPTION OF BUSINES

NOTE 1 - DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
NOTE 1 - DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 1 - DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES Description of Business FONAR Corporation (the “Company” or “FONAR”) is a Delaware corporation, which was incorporated on July 17, 1978. FONAR is engaged in the research, development, production and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging ("MRI") for the detection and diagnosis of human diseases. In addition to deriving revenues from the direct sale of MRI equipment, revenue is also generated from our installed-base of customers through our service and upgrade programs. FONAR, through its wholly-owned subsidiary Health Management Corporation of America ("HMCA") provides comprehensive management services to diagnostic imaging facilities. The services provided by the Company include development, administration, leasing of office space, facilities and medical equipment, provision of supplies, staffing and supervision of non-medical personnel, legal services, accounting, billing and collection and the development and implementation of practice growth and marketing strategies. On July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM.

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships. The operating activities of subsidiaries are included in the accompanying consolidated statements from the date of acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The most significant estimates relate to receivable allowances, intangible assets, income taxes and related tax asset valuation allowances, useful lives of property and equipment, contingencies, revenue recognition and the assessment of litigation. In addition, healthcare industry reforms and reimbursement practices will continue to impact the Company's operations and the determination of contractual and other allowance estimates. Actual results could differ from those estimates. Inventories Inventories consist of purchased parts, components and supplies, as well as work-in-process, and are stated at the lower of cost, determined on the first-in, first-out method, or market. Property and Equipment Property and equipment procured in the normal course of business is stated at cost. Property and equipment purchased in connection with an acquisition is stated at its estimated fair value, generally based on an appraisal. Property and equipment is being depreciated for financial accounting purposes using the straight-line method over their estimated useful lives. Leasehold improvements are being amortized over the shorter of the useful life or the remaining lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gains or losses are reflected in the results of operations. Expenses for maintenance and repairs are charged to operations. Renewals and betterments are capitalized. Maintenance and repair expenses totaled approximately $1,557,000, $1,451,000 and $1,116,000 for the years ended June 30, 2019, 2018 and 2017, respectively. The estimated useful lives in years are generally as follows: Diagnostic equipment 5–13 Research, development and demonstration equipment 3-7 Machinery and equipment 2-7 Furniture and fixtures 3-9 Leasehold improvements 2–10 Building 28 Long-Lived Assets The Company periodically assesses the recoverability of long-lived assets, including property and equipment and intangibles, other than goodwill, when there are indications of potential impairment, based on estimates of undiscounted future cash flows. The amount of impairment is calculated by comparing anticipated discounted future cash flows with the carrying value of the related asset. In performing this analysis, management considers such factors as current results, trends, and future prospects, in addition to other economic factors. Deferred Rent Rent expense is recorded on the straight-line method based on the total minimum rent payments required over the term of the lease. The cumulative difference between the lease expense recorded under this method and the contractual lease payment terms is recorded as deferred rent. Other Intangible Assets 1) Capitalized Software Development Costs Capitalization of software development costs begins upon the establishment of technological feasibility. Technological feasibility for the Company’s computer software is generally based upon achievement of a detail program design free of high risk development issues and the completion of research and development on the product hardware in which it is to be used. The establishment of technological feasibility and the ongoing assessment of recoverability of capitalized computer software development costs require considerable judgment by management with respect to certain external factors, including, but not limited to, technological feasibility, anticipated future gross revenue, estimated economic life and changes in software and hardware technology. Prior to reaching technological feasibility those costs are expensed as incurred and included in research and development. Amortization of capitalized software development costs commences when the related products become available for general release to customers. Amortization is provided on a product by product basis. The annual amortization is the greater of the amount computed using (a) the ratio that current gross revenue for a product bears to the total of current and anticipated future gross revenue for that product, or (b) the straight-line method over the remaining estimated economic life of the product. The Company periodically performs reviews of the recoverability of such capitalized software development costs. At the time a determination is made that capitalized amounts are not recoverable, based on the estimated cash flows to be generated from the applicable software, any remaining capitalized amounts are written off. 2) Patents and Copyrights Amortization is calculated on the straight-line basis over 15 years. 3) Non-Competition Agreements The non-competition agreements are being amortized on the straight line basis over the length of the agreement (7 years). 4) Customer Relationships Amortization is calculated on the straight line basis over 20 years. Goodwill Generally accepted accounting principles in the United States require the Company to perform a goodwill impairment test annually and more frequently when negative conditions or a triggering event arises. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit’s carrying amount, including goodwill to the fair value of the reporting unit. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered potentially impaired and a second step is performed to measure the amount of impairment loss, if any. Acquired assets and assumed liabilities Pursuant to ASC No. 805-10-25, if the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, but during the allowed measurement period not to exceed one year from the acquisition date, the Company adjusts the provisional amounts recognized at the acquisition date by means of adjusting the amount recognized for goodwill. Revenue Recognition Revenue on sales contracts for scanners, included in “product sales” in the accompanying consolidated statements of operations, is recognized under the percentage-of-completion method in accordance with FASB ASC 605-35, “Revenue Recognition – Construction-Type and Production-Type Contracts”. The Company manufactures its scanners under specific contracts that provide for progress payments. Production and installation take approximately three to six months. Revenue on scanner service contracts is recognized on the straight-line method over the related contract period, usually one year. Revenue from product sales (upgrades and supplies) is recognized upon shipment. Revenue under management contracts is recognized based upon contractual agreements for management services rendered by the Company primarily under various long-term agreements with various medical providers (the "PCs"). As of June 30, 2019, the Company has twenty two management agreements of which three are with PC’s owned by Raymond V. Damadian, M.D., Chairman of the Board of FONAR (“the Related medical practices”) and nineteen are with PC’s, which are all located in the state of New York (“the New York PC’s”), owned by two unrelated radiologists. The contractual fees for services rendered to the PCs consists of fixed monthly fees per diagnostic imaging facility ranging from approximately $54,000 to $481,000. All fees are re-negotiable at the anniversary of the agreements and each year thereafter. The Company records a provision for bad debts for estimated uncollectible fees, which is reflected in other operating expenses on the Statement of Operations. Revenue under lease contracts is recognized based upon contractual agreements for the leasing of medical equipment primarily under long term contracts to various unrelated PC’s. All fees are re-negotiable at the anniversary of the agreements and each year thereafter. On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue. The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2019. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Additionally, upon adoption of ASC 606 the allowance for doubtful accounts of approximately $22.7 million as of July 1, 2018 was reclassified as a component of net patient accounts receivable. Other than these changes in presentation on the condensed consolidated statement of operations and condensed consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated results of operations for the year ended June 30, 2019 and is not expected to have a material impact on its consolidated results of operations on a prospective basis. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenues, net of contractual allowances and discounts less the provision for bad debts for the years ended June 30, 2019, 2018 and 2017 are summarized in the following table. For the Year Ended June 30, 2019 2018 2017 Commercial Insurance/ Managed Care $ 5,218,656 $ 4,729,514 $ 4,904,892 Medicare/Medicaid 1,172,543 1,233,078 1,274,436 Workers' Compensation/Personal Injury 16,790,025 25,358,543 23,240,829 Other 1,026,312 7,844,278 6,980,443 Patient Fee Revenue, net of contractual allowances and discounts 24,207,536 39,165,413 36,400,600 Provision for Bad Debts — (17,896,528 ) (16,171,434 ) Net Patient Fee Revenue $ 24,207,536 $ 21,268,885 $ 20,229,166 Research and Development Costs Research and development costs are charged to expense as incurred. The costs of equipment that are acquired or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives. Advertising Costs Advertising costs are expensed as incurred. Advertising expense approximated $538,000, $607,000 and $531,000 for the years ended June 30, 2019, 2018 and 2017, respectively. Shipping Costs The Company’s shipping and handling costs are included in revenue from product sales and the related expense included in costs related to product sales is $13,695, $9,370 and $8,224 for the years ended June 30, 2019, 2018 and 2017, respectively. Income Taxes Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Customer Advances Cash advances and progress payments received on sales orders are reflected as customer advances until such time as revenue recognition occurs. Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class Method”, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share for the years ended June 30, 2019, 2018 and 2017. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the years ended June 30, 2019, 2018 and 2017, diluted EPS for common shareholders includes 127,504 shares upon conversion of Class C Common. June 30, 2019 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 12,025,078 $ 11,278,997 $ 190,012 Denominator: Weighted average shares outstanding 6,354,103 6,354,103 382,513 Basic income per common share $ 1.89 $ 1.78 $ 0.50 Diluted Denominator: Weighted average shares outstanding 6,354,103 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,481,607 382,513 Diluted income per common share $ 1.74 $ 0.50 June 30, 2018 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 21,230,802 $ 19,899,823 $ 338,974 Denominator: Weighted average shares outstanding 6,287,510 6,287,510 382,513 Basic income per common share $ 3.38 $ 3.16 $ 0.89 Diluted Denominator: Weighted average shares outstanding 6,287,510 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,415,014 382,513 Diluted income per common share $ 3.10 $ 0.89 June 30, 2017 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 19,620,621 $ 18,390,586 $ 313,266 Denominator: Weighted average shares outstanding 6,161,599 6,161,599 382,513 Basic income per common share $ 3.18 $ 2.98 $ 0.82 Diluted Denominator: Weighted average shares outstanding 6,161,599 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,289,103 382,513 Diluted income per common share $ 2.92 $ 0.82 Cash and Cash Equivalents Cash and cash equivalents includes cash on hand, cash in banks, investments in certificates of deposit with original maturities of 90 days or less, and money market funds. Short Term Investments Short term investments include certificates of deposit with original maturities of greater than 90 days. Concentration of Credit Risk Cash: The Company maintains its cash and cash equivalents with various financial institutions, which exceed federally insured limits throughout the year. At June 30, 2019, the Company had cash on deposit of approximately $11,842,000 in excess of federally insured limits of $250,000. Related Parties: Net revenues from related parties accounted for approximately 11%, 11% and 11% of the consolidated net revenues for the years ended June 30, 2019, 2018 and 2017, respectively. Net management fee receivables from the related party medical practices accounted for approximately 13%, 12% and 13% of the consolidated accounts receivable for the years ended June 30, 2019, 2018 and 2017, respectively. See Note 3 regarding the Company’s concentrations in the healthcare industry. Fair Value of Financial Instruments The financial statements include various estimated fair value information at June 30, 2019 and 2018, as required by ASC topic 820, "Disclosures about Fair Value of Financial Instruments". Such information, which pertains to the Company's financial instruments, is based on the requirements set forth in that Statement and does not purport to represent the aggregate net fair value to the Company. The Company has established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring and revaluing fair value. These tiers include, Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value: Cash and cash equivalents: The carrying amount approximates fair value because of the short-term maturity of those instruments. Short term investments: The carrying amount approximates fair value because of the short-term maturity of those instruments. Such amounts include Certificates of Deposits with original maturities greater than 90 days. These securities are classified as Level 1. Receivable and accounts payable: The carrying amounts approximate fair value because of the short maturity of those instruments. Notes receivable: The carrying amount approximates fair value because the discounted present value of the cash flow generated by the parties approximates the carrying value of the amounts due to the Company. Long-term debt and notes payable: The carrying amounts of debt and notes payable approximate fair value due to the length of the maturities, the interest rates being tied to market indices and/or due to the interest rates not being significantly different from the current market rates available to the Company. All of the Company's financial instruments are held for purposes other than trading. Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled in exchange for goods and services as it transfers control to its customers. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The Company earns revenue from the sale of scanners, maintenance contracts, product upgrades, patient services and management fees. Under the new guidance, the reporting for patient services revenue will be reported differently. All other streams of revenue will not be impacted by the new guidance. The primary change for healthcare providers under the new guidance relates to revenue generated from patient services, with patient responsibility for payment. Under the new guidance, the Company is required to report an implicit price concession (both initially and for the subsequent changes in estimates) as a reduction of revenues as opposed to bad debt expense as a component of operating expenses. The Company will record any changes in expectation of collection amounts due to patient specific events that suggests that the patient no longer has the ability and intent to pay the amount due through the bad debt expense, as that is more indicative of a change in the customer’s credit worthiness as opposed to change in the transaction price. The new standard supersedes most current revenue guidance, including industry-specific guidance. The guidance became effective for the Company on July 1, 2018 and as part of adopting the standard, the Company identified revenue streams of like contracts to allow for ease of implementation. The Company used primarily a portfolio approach to apply the new model to classes of customers with similar characteristics. The impact of adopting the new standard on our total revenue; and income from operations is not material. While the adoption of ASU 2014-09 will impact the presentation of net operating revenues in our Consolidated Statements of Operations and will impact certain disclosures, it will not materially impact our financial position, results of operations or cash flows. There was no cumulative effect of a change in accounting principle recorded related to the adoption of ASU 2014-09 on July 1, 2018. In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company has adopted this guidance on our Consolidated Financial Statements and it has no impact on the Company’s financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases Leases Targeted Improvements FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of June 30, 2019 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2019 or 2018, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective. Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported net income for any periods presented.

NOTE 3 - ACCOUNTS RECEIVABLE, M

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	12 Months Ended
	Jun. 30, 2019
Receivables [Abstract]
NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Accounts Receivable Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided. Medical Receivable Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that will not be collected. The Company continuously monitors collections from its clients and maintains an allowance for bad debts based upon the Company’s historical collection experience. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site. Management and Other Fees Receivable The Company’s receivables from the related and non-related professional corporations (“PCs”) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PCs of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations. Payment of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 67%, 65% and 62%, respectively, of the PCs’ 2019, 2018 and 2017 net revenues were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the consolidated financial statements and have historically been within management's expectations. Net revenues from management and other fees charged to the related party medical practices accounted for approximately 11%, 11% and 11%, of the consolidated net revenues for the years ended June 30, 2019, 2018 and 2017, respectively. Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related party medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. The following table sets forth the number of our facilities for the years ended June 30, 2019, 2018 and 2017. For The Year Ended June 30, 2019 2018 2017 Total Facilities Owned or Managed (at Beginning of Year) 26 26 25 Facilities Added by: Acquisition — — 1 Internal development — — — Managed Facilities Closed — — — Total Facilities Owned or Managed (at End of Year) 26 26 26

NOTE 4 - COSTS AND ESTIMATED EA

NOTE 4 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
NOTE 4 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS AND CUSTOMER ADVANCES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 4 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS Information relating to uncompleted contracts as of June 30, 2019 and 2018 is as follows: As of June 30, 2019 2018 Costs incurred on uncompleted contracts $ 448,437 $ 448,437 Estimated earnings 1,088,675 309,248 1,537,112 757,685 Less: Billings to date 1,012,002 671,047 $ 525,110 $ 86,638

NOTE 5 - INVENTORIES

NOTE 5 - INVENTORIES	12 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
NOTE 5 - INVENTORIES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 5 – INVENTORIES Inventories included in the accompanying consolidated balance sheets consist of: As of June 30, 2019 2018 Purchased parts, components and supplies $ 1,639,777 $ 1,312,299 Work-in-process 158,389 119,081 $ 1,798,166 $ 1,431,380

NOTE 6 - PROPERTY AND EQUIPMENT

NOTE 6 - PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
NOTE 6 - PROPERTY AND EQUIPMENT	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 6 - PROPERTY AND EQUIPMENT Property and equipment, at cost, less accumulated depreciation and amortization, at June 30, 2019 and 2018, is comprised of: As of June 30, 2019 2018 Diagnostic equipment $ 26,090,218 $ 24,296,957 Research, development and demonstration equipment 3,605,906 2,987,531 Machinery and equipment 2,069,055 2,069,055 Furniture and fixtures 3,122,102 3,036,539 Leasehold improvements 8,023,292 7,165,035 Building 939,614 939,614 43,850,187 40,494,731 Less: Accumulated depreciation and amortization 26,864,570 24,002,453 $ 16,985,617 $ 16,492,278 Depreciation and amortization of property and equipment for the years ended June 30, 2019, 2018 and 2017 was $2,862,117, $2,748,174 and $2,303,554, respectively.

NOTE 7 - OTHER INTANGIBLE ASSET

NOTE 7 - OTHER INTANGIBLE ASSETS	12 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
NOTE 7 - OTHER INTANGIBLE ASSETS	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 7 - OTHER INTANGIBLE ASSETS Other intangible assets, net of accumulated amortization, at June 30, 2019 and 2018 are comprised of: As of June 30, 2019 2018 Capitalized software development costs $ 7,004,847 $ 7,004,847 Patents and copyrights 4,964,199 4,835,806 Non-competition agreements 4,100,000 4,100,000 Customer relationships 3,800,000 3,800,000 19,869,046 19,740,653 Less: Accumulated amortization 15,113,371 14,138,997 $ 4,755,675 $ 5,601,656 The estimated amortization of other intangible assets for the five years ending June 30, 2024 and thereafter is as follows: For the Years Ending June 30, Total Patents and Copyrights Non- Customer Relationships 2020 $ 771,830 $ 191,353 $ 390,477 $ 190,000 2021 381,860 191,860 — 190,000 2022 380,470 190,470 — 190,000 2023 383,929 193,929 — 190,000 2024 375,561 185,561 — 190,000 Thereafter 2,462,025 815,358 — 1,646,667 $ 4,755,675 $ 1,768,531 $ 390,477 $ 2,596,667 The weighted average amortization period for other intangible assets is 11.5 years and they have no expected residual value. Information related to the above intangible assets for the years ended June 30, 2019, 2018 and 2017 is as follows: As of June 30, 2019 2018 2017 Balance – Beginning of Year $ 5,601,656 $ 6,644,504 $ 7,719,358 Amounts capitalized 128,393 108,829 155,156 Software or patents written off — — — ) Amortization (974,374 ) (1,151,677 ) (1,230,010 ) Balance – End of Year $ 4,755,675 $ 5,601,656 $ 6,644,504 Amortization of patents and copyrights for the years ended June 30, 2019, 2018 and 2017 amounted to $198,660, $202,630 and $194,296, respectively. Amortization of capitalized software development costs for the years ended June 30, 2019, 2018 and 2017 was $0, $173,333 and $260,000, respectively. Amortization of non-competition agreements for the years ended June 30, 2019, 2018 and 2017 amounted to $585,714, $585,714 and $585,714, respectively. Amortization of customer relationships for the years ended June 30, 2019, 2018 and 2017 amounted to $190,000, $190,000 and $190,000, respectively.

NOTE 8 - CAPITAL STOCK

NOTE 8 - CAPITAL STOCK	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
NOTE 8 - CAPITAL STOCK	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 8 - CAPITAL STOCK Common Stock Cash dividends payable on the common stock shall, in all cases, be on a per share basis, one hundred twenty percent (120%) of the cash dividend payable on shares of Class B common stock and three hundred sixty percent (360%) of the cash dividend payable on a share of Class C common stock. Class B Common Stock Class B common stock is convertible into shares of common stock on a one-for-one basis. Class B common stock has 10 votes per share. There were 146 of such shares outstanding at June 30, 2019, 2018 and 2017. Class C Common Stock On April 3, 1995, the stockholders ratified a proposal creating a new Class C common stock and authorized the exchange offering of three shares of Class C common stock for each share of the Company's outstanding Class B common stock. The Class C common stock has 25 votes per share, as compared to 10 votes per share for the Class B common stock and one vote per share for the common stock. The Class C common stock was offered on a three-for-one basis to the holders of the Class B common stock. Although having greater voting power, each share of Class C common stock has only one-third of the rights of a share of Class B common stock to dividends and distributions. Class C common stock is convertible into shares of common stock on a three-for-one basis. Class A Non-Voting Preferred Stock On April 3, 1995, the stockholders ratified a proposal consisting of the creation of a new class of Class A non-voting preferred stock with special dividend rights and the declaration of a stock dividend on the Company's common stock consisting of one share of Class A non-voting preferred stock for every five shares of common stock. The stock dividend was payable to holders of common stock on October 20, 1995. Class A non-voting preferred stock issued pursuant to such stock dividend approximates 313,000 shares. The Class A non-voting preferred stock is entitled to a special dividend equal to 3-1/4% of first $10 million, 4-1/2% of next $20 million and 5-1/2% on amounts in excess of $30 million of the amount of any cash awards or settlements received by the Company in connection with the enforcement of five of the Company's patents in its patent lawsuits, less the revised special dividend payable on the common stock with respect to one of the Company's patents. The Class A non-voting preferred stock participates on an equal per share basis with the common stock in any dividends declared and ranks equally with the common stock on distribution rights, liquidation rights and other rights and preferences (other than the voting rights). Stock Bonus Plans On April 23, 2010, the Board approved the 2010 Stock Bonus Plan. The plan entitles the Company to reserve 2,000,000 shares of common stock. On August 10, 2010, the Company filed Form S-8 to register the 2,000,000 shares. As of June 30, 2019, 646,905 shares of common stock of FONAR were available for future grant under this plan. For the years ended June 30, 2019, 2018 and 2017, 69,971, 0 and 193,461 shares were issued respectively. Options The Company had stock option plans, which provide for the awarding of incentive and non-qualified stock options to employees, directors and consultants who may contribute to the success of the Company. The options granted vest either immediately or ratably over a period of time from the date of grant, typically three or four years, at a price determined by the Board of Directors or a committee of the Board of Directors, generally the fair value of the Company's common stock at the date of grant. The options must be exercised within ten years from the date of grant.

NOTE 9 - CONTROLLING AND NONCON

NOTE 9 - CONTROLLING AND NONCONTROLLING INTERESTS	12 Months Ended
	Jun. 30, 2019
Noncontrolling Interest [Abstract]
NOTE 9 - CONTROLLING AND NON CONTROLLING INTERESTS	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 9 – CONTROLLING AND NONCONTROLLING INTERESTS On February 13, 2013 the Company entered into an agreement with outside investors to acquire a 50.5% controlling interest in a newly formed limited liability company, Health Diagnostics Management LLC (HDM). According to the February 13, 2013 LLC operating agreement of HDM there are two classes of members; Class A members and one Class B member. The Class A members have an ownership interest of 49.5% of HDM. The Class B member (HMCA) has an ownership of 50.5% of HDM. On all matters on which members may vote every member is entitled to cast the percentage of votes equal to their percentage of ownership interest. Profits and losses on all items of income, gain or loss, deductions or other allocations of the Company will be allocated among the members in the same proportions as their membership interests in the Company bear to all the Class A and Class B membership interests of the Company in the aggregate outstanding. All of the depreciation and amortization of the assets of the Company will be allocated solely to the Class A members, unless and until their interests have been redeemed by the Company in full pursuant to the provisions of the operating agreement. The Company contributed $20,200,000 to HDM and the group of outside investors contributed $19,800,000 for its non-controlling membership interest. On March 5, 2013 HDM purchased from Health Diagnostics, LLC (“HD”) and certain of its subsidiaries, a business managing twelve (12) Stand-Up MRI Centers and two (2) other scanning centers located in the States of New York and Florida for a total purchase price (including consideration of $1.5 million to outside investors) aggregating $35.9 million. Concurrently with the acquisition, HDM entered into several consulting and non-competition agreements for a consideration of $4.1 million. The acquisition was accounted for using the purchase method in accordance with ASC 805, “Business Combinations”. The Company recognized and measured goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. On January 8, 2015, the Company purchased 20% of the Class A members ownership interest at a cost of $4,971,094. The Company has a 60.4% ownership interest in HDM after this transaction. Amount of each class of HDM members’ equity as of June 30, 2019, 2018 and 2017 June 30, 2019 June 30, 2018 June 30, 2017 Class A Members Class B Member Class A Members Class B Member Class A Members Class B Member Opening Members’ Equity $ 3,559,182 $ 31,775,922 $ 5,472,799 $ 27,988,982 $ 8,396,575 $ 23,314,842 Share of Net Income 5,196,543 20,167,864 4,221,383 18,101,940 4,058,177 16,947,624 Distributions (6,600,000 ) (15,400,000 ) (6,135,000 ) (14,315,000 ) (6,981,953 ) (12,273,484 ) Ending Members’ Equity $ 2,155,725 $ 36,543,786 $ 3,559,182 $ 31,775,922 $ 5,472,799 $ 27,988,982

NOTE 10 - LONG-TERM DEBT, NOTES

NOTE 10 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES	12 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
NOTE 10 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 10 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES Long-term debt, notes payable and capital leases consist of the following: 2019 2018 Note payable requiring monthly payments of interest at a rate of 7% until May 2009 followed by 240 monthly payments of $4,472 through October 2026. The loan is collateralized by a building with a net book value of $481,666 as of June 30, 2019. $ 306,056 $ 336,781 The revolving credit note was extended to August 2020. The Company can prepay the loan in whole or part in multiples of $100,000 at any time without penalty. The note bears interest at a rate of 5.25% per annum and is payable monthly. The loan is collateralized by substantially all of the Company’s assets. The loan also contains certain financial covenants that must be met on a periodic basis. The note was paid in full September 2, 2014. The Company still has the ability to draw down on the line. — — Other (including capital leases for property and equipment). 7,586 7,586 313,642 344,367 Less: Current portion 40,530 38,332 $ 273,112 $ 306,035 The maturities of long-term debt over the next five years and thereafter are as follows: Years Ending June 30, 2020 $ 40,530 2021 35,416 2022 38,013 2023 40,820 2024 43,767 Thereafter 115,096 $ 313,642

NOTE 11 - INCOME TAXES

NOTE 11 - INCOME TAXES	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
NOTE 11 - INCOME TAXES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 11 - INCOME TAXES ASC topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC topic 740. The Company believes there are no uncertain tax positions in prior years tax filings and therefore it has not recorded a liability for unrecognized tax benefits. In accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses. The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2015 for federal and 2014 for state. The Company has recorded a deferred tax asset of $20,937,747 and a deferred tax liability of $243,267 as of June 30, 2019, primarily relating to its net operating loss carryforwards of approximately $65,792,000 available to offset future taxable income through 2030. The net operating losses begin to expire in 2023 for federal tax and state income tax purposes. Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of June 30, 2019, no such changes in ownership have occurred. The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry, and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, (principally related to research and development tax credits). A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation. The valuation allowance for deferred tax assets decreased during the year ended June 30, 2019, by approximately $2,350,000. The valuation allowance decreased by approximately $27,600,000 during the year ended June 30, 2018, of which $16,000,000 was the result of the revalued deferred tax assets due to the Tax Cuts and Jobs Act and the benefits expected to be realized from the usage of net operating losses given the Company’s current and projected profitable operations. Components of the provision (benefit) for income taxes are as follows: Years Ended June 30, 2019 2018 2017 Current: Federal $ — $ 185,000 $ 250,000 State 250,000 265,000 357,235 Subtotal 250,000 450,000 607,235 Deferred: Federal deferred taxes 1,685,299 (4,132,590 ) (4,552,702 ) State deferred taxes 70,221 (787,160 ) (416,967 ) AMT Credits — (1,200,000 ) — Subtotal 1,755,520 (6,119,750 ) (4,969,669 ) $ 2,005,520 $ (5,669,750 ) $ (4,362,434 ) A reconciliation of the federal statutory income tax rate to the Company's effective tax rate as reported is as follows: Years Ended June 30, 2019 2018 2017 Taxes at federal statutory rate 21.0 % 27.7 % 35.0 % State and local income taxes (benefit), net of federal benefit 4.0 % 4.0 % 4.0 % Non Controlling interest (5.8 )% (6.8 )% (8.2 )% Permanent differences (3.5 )% 0.1 % 0.1 % Tax Cuts and Jobs Act Rate Change 0 % (26.9 )% 0 % Decrease in the valuation allowance (2.6 )% (18.5 )% (55.7 )% AMT Credits 0 % (6.4 )% 0 % Other (4.2 )% (1.8 )% 2.2 % Effective income tax rate 8.9 % (28.6 )% (22.6 )% The Tax Cuts and Jobs Act was signed into law on December 22, 2017 and makes numerous changes to the Internal Revenue Code. Among other changes, the Act reduces the US corporate income tax rate to 21% effective January 1, 2018. Because the Act became effective mid-way through the Company’s tax year, the Company had a US statutory income tax rate of 27.7% for the fiscal 2018 and will have a 21% statutory income tax rate for fiscal years thereafter. Under ASC740, Accounting for Income Taxes, the enactment of the Tax Act also requires companies, to recognize the effects of changes in tax laws and rates on deferred tax assets and liabilities and the retroactive effects of changes in tax laws in the period in which the new legislation is enacted. The Company’s gross deferred tax assets and liabilities were revalued from 35% to 21%. As of June 30, 2019, the Company has net operating loss (“NOL”) carryforwards of approximately $65,792,000 that will be available to offset future taxable income. The utilization of certain of the NOLs is limited by separate return limitation year rules pursuant to Section 1502 of the Internal Revenue Code. The Company has, for federal income tax purposes, research and development tax credits and investments tax credits carryforwards aggregating $4,602,000. However, the realization of these credits may be limited as a result of expiring prior to their utilization. These credits can only be applied after all net operating losses have been used, which expire through 2030. As such, the Company has established a valuation reserve for anticipated unused credits of $3,902,000. As of June 30, 2019, the Company has $1,200,000 in alternative minimum tax credits. In connection with tax reform, these credits have been eliminated. Tax reform allows for corporations to carryover such unused tax credits to offset regular tax or apply for a cash refund. As of June 30, 2018, the Company recorded an income tax receivable for expected cash refunds. The Company anticipates receiving its first installment of reimbursement of $600,000 with the filiing of its June 30, 2019 income tax return to be filed in fiscal 2020. In addition, for New York State income tax purposes, the Company has tax credit carryforwards aggregating approximately $250,000 which, are accounted for under the flow-through method. The utilization of these credits is also expected to be limited. The Company is also under audit with New York State for income tax and does not expect any material adjustments. Significant components of the Company's deferred tax assets and liabilities at June 30, 2019 and 2018 are as follows: June 30, 2019 2018 Deferred tax assets: Allowance for doubtful accounts $ 3,011,480 $ 3,262,504 Non-deductible accruals 861,345 752,595 Net operating carryforwards 16,448,054 20,665,597 Tax credits 4,601,801 4,330,769 Inventory 65,081 55,514 Property and equipment and depreciation 192,133 213,781 25,179,894 29,280,760 Valuation allowance (4,242,147 ) (6,591,749 ) Total deferred tax assets 20,937,747 22,689,011 Intangibles (243,267 ) (239,011 ) Total deferred tax liabilities (243,267 ) (239,011 ) Net deferred tax asset $ 20,694,480 $ 22,450,000

NOTE 12 - OTHER CURRENT LIABILI

NOTE 12 - OTHER CURRENT LIABILITIES	12 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
NOTE 12 - OTHER CURRENT LIABILITIES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 12 - OTHER CURRENT LIABILITIES Included in other current liabilities are the following: June 30, 2019 2018 Accrued salaries, commissions and payroll taxes $ 3,897,833 $ 3,438,087 Litigation accruals 145,029 145,029 Sales tax payable 1,671,488 2,092,403 Legal and other professional fees 125,567 119,262 Accounting fees 105,000 125,000 Self-funded health insurance reserve 67,825 79,129 Accrued interest and penalty 1,054,134 1,497,429 Other 510,540 681,656 $ 7,577,416 $ 8,177,995

NOTE 13 - COMMITMENTS AND CONTI

NOTE 13 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
NOTE 13 - COMMITMENTS AND CONTINGENCIES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 13 - COMMITMENTS AND CONTINGENCIES Leases The Company rents its operating facilities and certain equipment, pursuant to operating lease agreements expiring at various dates through June 2028. The leases for certain facilities contain escalation clauses relating to increases in real property taxes as well as certain maintenance costs. Future minimum operating lease commitments consisted of the following at June 30, 2019: Year Ending June 30, Facilities And Equipment 2020 $ 4,655,396 2021 4,323,037 2022 3,396,273 2023 2,778,617 2024 2,350,193 Thereafter 5,081,636 Total minimum obligations $ 22,585,152 Rent expense for operating leases approximated $4,688,000, $4,762,000 and $4,505,000, for the years ended June 30, 2019, 2018 and 2017, respectively. The Company received approval from the Suffolk County IDA on February 29, 2016 of a 50% property tax abatement, valued at $440,000, over a 10 year period commencing January 2017. Employee Benefit Plans The Company has a non-contributory 401(k) Plan (the “401(k) Plan”). The 401(k) Plan covers all non-union employees who are at least 21 years of age with no minimum service requirements. There were no employer contributions to the Plan for the years ended June 30, 2019, 2018 and 2017. The stockholders of the Company approved the 2000 Employee Stock Purchase Plan (“ESPP”) at the Company’s annual stockholders’ meeting in April 2000. The ESPP provides for eligible employees to acquire common stock of the Company at a discount, not to exceed 15%. This plan has not been put into effect as of June 30, 2019. Stipulation Agreements The Company has entered into stipulation agreements with a number of its creditors that in the aggregate total $142,299, which is included in other current liabilities and other liabilities on the Company’s balance sheet as of June 30, 2019. The monthly payments total $15,859. Litigation The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company. Matt Malek Madison v. Fonar Corporation, United States District Court, Northern District of California, was commenced by plaintiff on August 27, 2007 to recover a down payment for a scanner in the amount of $300,000, with interest. The plaintiff sought costs of suit and attorney’s fees as well. The Company answered the complaint and sued the plaintiff for breach of contract in the amount of $450,000. Although down payments are usually expressly non-refundable in the Company’s quotations and agreements, in this case, the quotation contemplated the sale of four scanners, and provided that the deposit would be refundable with interest, if the customer were unable to find suitable locations in the San Francisco Bay area. The issue was whether the customer made a good faith effort to find locations; the Company’s position was that the customer did not. The case went to trial before a judge; the parties submitted post-trial briefs, and judgment was awarded to the plaintiff. The Company appealed the trial court’s decision, but on January 31, 2012, the U.S. Court of Appeals for the 9th Circuit affirmed the lower court’s decision awarding the plaintiff the $300,000 deposit with prejudgment interest from July 1, 2006. The Company sought to have the Court of Appeals reconsider the decision en banc, (by all or a larger number of the judges on the Circuit Court of Appeals), but this was not granted. During October 2016, the Company settled with the plaintiff for $300,000. Other Matters The Company is also delinquent in filing sales tax returns for certain states, for which the Company has transacted business. The Company has recorded tax obligations of approximately $1,671,000 plus interest and penalties of approximately $1,054,000. The Company is in the process of determining its regulatory requirements in order to become compliant. The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $100,000 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of June 30, 2019 and 2018, the Company had approximately $68,000 and $79,000, respectively, in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the consolidated balance sheets. The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the years covered by this report.

NOTE 14 - SUPPLEMENTAL CASH FLO

NOTE 14 - SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Jun. 30, 2019
Supplemental Cash Flow Elements [Abstract]
NOTE 14 - SUPPLEMENTAL CASH FLOW INFORMATION	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 14 - SUPPLEMENTAL CASH FLOW INFORMATION During the years ended June 30, 2019, 2018 and 2017, the Company paid $165,172, $44,767 and $162,022 for interest, respectively. During the years ended June 30, 2019, 2018 and 2017, the Company paid $304,575, $345,000 and $739,889 for income taxes, respectively. During the years ended June 30, 2019, 2018 and 2017, the Company issued 69,971, 0 and 106,600 shares of common stock for costs and expenses totaling $1,954,744, $0 and $2,239,292, respectively.

NOTE 15 - DUE TO RELATED MEDICA

NOTE 15 - DUE TO RELATED MEDICAL PRACTICES	12 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
NOTE 15 - DUE TO RELATED MEDICAL PRACTICES	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 15 – RELATED PARTY TRANSACTIONS The CEO and President of the Company is a minority owner of a billing company, which performs billing and collection services with respect to No-Fault and Workers’ Compensation claims of the Company’s clients. The monthly fee charged to the Company is $85,000. On June 1, 2017, the Company also entered into a one year renewable agreement to provide IT services to the billing company for a monthly fee of $23,884. The agreement was renewed on June 1, 2019 for another year. Bensonhurst MRI Limited Partnership, in which the CEO and President of the Company holds an interest, is party to an agreement with the Company for the service and maintenance of its Upright MRI Scanner for a price of $110,000 per annum. A limited liability company of which the CEO and President of the Company is an owner also had a 1.375% interest in Yonkers Diagnostic Management, LLC, a 4.5% interest in Turnkey Services of New York, LLC and a 4.3% interest in TK2 Equipment Management, LLC. Entities in which the Executive Vice President and COO and his family had an interest had a 0.75% in Yonkers and a 5.9% in TK2 Equipment Management . The Company acquired these entities, or the portion thereof not already owned by the Company, through a series of merger transactions for $1,780,000 in the case of Yonkers, $1,147,715 in the case of Turnkey Services and $3,075,852 in the case of TK2 Equipment Management. A company of which the CEO and President of the Company is an owner and a company in which the Executive Vice President and COO has an interest also hold a 1.7% and 2.8% interest, respectively, in Turnkey Management of Great Neck, LLC, an entity for which the Company performed management services. The Company acquired this through a merger transaction for $1,312,766.

NOTE 16 - SEGMENT AND RELATED I

NOTE 16 - SEGMENT AND RELATED INFORMATION	12 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
NOTE 16 - SEGMENT AND RELATED INFORMATION	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 16 - SEGMENT AND RELATED INFORMATION The Company provides segment data in accordance with the provisions of ASC topic 280, “Disclosures about Segments of an Enterprise and Related Information”. The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. All intersegment sales are market-based. The Company evaluates performance based on income or loss from operations. Summarized financial information concerning the Company’s reportable segments is shown in the following table: Manufacturing and Servicing of Medical Management of Diagnostic Imaging Fiscal 2019: Equipment Center Totals Net revenues from external customers $ 10,013,394 $ 77,179,493 $ 87,192,887 Intersegment net revenues * $ 907,084 $ — $ 907,084 (Loss) Income from operations $ (3,419,944 ) $ 25,554,136 $ 22,134,192 Depreciation and amortization $ 370,001 $ 3,466,490 $ 3,836,491 Compensatory element of stock issuances $ 1,990,380 $ — $ 1,990,380 Total identifiable assets $ 25,065,808 $ 105,198,093 $ 130,263,901 Capital expenditures $ 746,768 $ 2,737,081 $ 3,483,849 Fiscal 2018: Net revenues from external customers $ 9,837,269 $ 71,678,725 $ 81,515,994 Intersegment net revenues * $ 901,250 $ — $ 901,250 (Loss) Income from operations $ (2,982,778 ) $ 22,666,989 $ 19,684,211 Depreciation and amortization $ 353,307 $ 3,546,544 $ 3,899,851 Compensatory element of stock issuances $ 1,954,744 $ — $ 1,954,744 Total identifiable assets $ 32,364,298 $ 85,946,647 $ 118,310,945 Capital expenditures $ 346,608 $ 2,540,169 $ 2,886,777 Fiscal 2017: Net revenues from external customers $ 11,219,188 $ 66,817,398 $ 78,036,586 Intersegment net revenues * $ 1,200,000 $ — $ 1,200,000 (Loss) Income from operations $ (2,292,312 ) $ 21,388,392 $ 19,096,080 Depreciation and amortization $ 324,550 $ 3,209,014 $ 3,533,564 Compensatory element of stock issuances $ 2,397,276 $ — $ 2,397,276 Total identifiable assets $ 29,103,809 $ 69,658,676 $ 98,762,566 Capital expenditures $ 212,983 $ 2,793,331 $ 3,006,314 * Amounts eliminated in consolidation Export Product Sales The Company’s areas of operations are principally in the United States. The Company had export sales of medical equipment amounting to 5.3%, 41.5% and 55.9% of product sales revenues to third parties for the years ended June 30, 2019, 2018 and 2017, respectively. The foreign product sales, as a percentage of product sales to unrelated parties, were made to customers in the following countries: For the Years Ended June 30, 2019 2018 2017 United Arab Emirates — % 7.1 % 45.4 % Canada .3 — — England .3 29.9 4.8 Germany — 4.5 — Puerto Rico 4.7 — 5.7 5.3 % 41.5 % 55.9 % Foreign Service and Repair Fees The Company’s areas of service and repair are principally in the United States. The Company had foreign revenues of service and repair of medical equipment amounting to 5.9%, 5.0% and 4.6% of consolidated net service and repair fees for the years ended June 30, 2019, 2018 and 2017, respectively. Foreign service and repair fees, as a percentage of total service and repair fees, were provided principally to the following countries: For the Years Ended June 30, 2019 2018 2017 Puerto Rico 1.6 % 1.5 % 1.2 % Switzerland 0.3 0.2 0.2 Germany 1.4 1.3 1.4 England 0.6 0.6 0.5 United Arab Emirates 0.3 0.3 — Canada 0.4 — 0.1 Greece 0.3 0.2 0.2 Australia 1.0 0.9 1.0 5.9 % 5.0 % 4.6 % The Company does not have any material assets outside of the United States.

NOTE 17 - ALLOWANCE FOR DOUBTFU

NOTE 17 - ALLOWANCE FOR DOUBTFUL ACCOUNTS	12 Months Ended
	Jun. 30, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
NOTE 17 - ALLOWANCE FOR DOUBTFUL ACCOUNTS	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 17 – ALLOWANCE FOR DOUBTFUL ACCOUNTS The following represents a summary of allowance for doubtful accounts for the years ended June 30, 2019, 2018 and 2017, respectively: Description Balance Additions (1) Deductions Balance Accounts receivable $ 190,244 $ — $ — $ 190,244 Management and other fees receivable 10,983,022 (1,578,078 ) — 9,404,944 Management and other fees receivable - related medical practices 1,711,385 599,346 — 2,310,731 Medical receivables 22,727,698 — 22,727,698 — Description Balance June 30, 2017 Additions Deductions Balance June 30, 2018 Accounts receivables $ 190,244 $ — $ — $ 190,244 Management and other fees receivable 12,859,750 (1,744,064 ) 132,664 10,983,022 Management and other fees receivable - related medical practices 582,001 1,129,384 — 1,711,385 Medical receivables 19,853,318 17,896,528 15,022,148 22,727,698 Description Balance June 30, 2016 Additions Deductions Balance June 30, 2017 Accounts receivables $ 284,279 $ — $ 94,035 $ 190,244 Management and other fees receivable 13,553,005 (104,424 588,831 12,859,750 Management and other fees receivable - related medical practices 392,505 582,001 392,505 582,001 Medical receivables 17,451,782 16,171,434 12,547,160 19,853,318 (1) Included in provision for bad debts.

NOTE 18 - QUARTERLY FINANCIAL D

NOTE 18 - QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
	Jun. 30, 2019
Note 18 - Quarterly Financial Data
NOTE 18 - QUARTERLY FINANCIAL DATA (UNAUDITED)	Quarterly financial data (Unaudited) (000’s omitted, except per share data) September 30, 2018 December 31, 2018 March 31, 2019 June 30, 2019 Total Total Revenues – Net $ 20,705 $ 21,225 $ 22,779 $ 22,484 $ 87,193 Total Costs and Expenses 15,163 15,245 16,171 18,480 65,059 Net Income 4,492 4,864 5,201 2,665 17,222 Basic Net Income Per Common Share Available to Common Stockholders $ 0.49 $ 0.52 $ 0.57 $ 0.20 $ 1.78 Diluted Net Income Per Common Share Available to Common Stockholders $ 0.48 $ 0.51 $ 0.56 $ 0.19 $ 1.74 September 30, 2017 December 31, 2017 March 31, 2018 June 30, 2018 Total Total Revenues – Net $ 19,334 $ 20,168 $ 20,979 $ 21,035 $ 81,516 Total Costs and Expenses 14,549 14,358 16,577 16,348 61,832 Net Income 4,601 5,240 4,262 11,349 25,452 Basic Net Income Per Common Share Available to Common Stockholders $ 0.55 $ 0.62 $ 0.52 $ 1.47 $ 3.16 Diluted Net Income Per Common Share Available to Common Stockholders $ 0.54 $ 0.61 $ 0.51 $ 1.44 $ 3.10

NOTE 19 - BUSINESS COMBINATIONS

NOTE 19 - BUSINESS COMBINATIONS	12 Months Ended
	Jun. 30, 2019
Business Combinations [Abstract]
NOTE 19 - BUSINESS COMBINATIONS	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 19 – BUSINESS COMBINATIONS Acquisitions On June 15, 2017, the Company purchased 100% interest in Turnkey Equipment Management of Great Neck, LLC. The consideration and net assets acquired is as follows: Cash Paid $ 1,312,769 Security deposit 23,775 Total Consideration 1,336,544 Net assets at Fair Value 731,582 Goodwill $ 604,962 On March 20, 2017, the Company purchased 100% interest in Radwell Leasing LLC and Radwell LLC. The net assets acquired and consideration is as follows: Diagnostic Equipment $ 544,375 Leasehold Improvements 126,237 Total Net Assets Acquired $ 670,612 Stock issued as consideration $ 791,210 Less cash received - Net (120,598 ) Total Consideration $ 670,612 Pro forma Results The results of operations of Radwell Leasing LLC, Radwell LLC and Turnkey Equipment of Great Neck LLC were diminutive and did not affect the proforma results of operations.

NOTE 21 - SUBSEQUENT EVENTS

NOTE 21 - SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
NOTE 20 - SUBSEQUENT EVENTS	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 20 – SUBSEQUENT EVENTS The Company evaluates events that have occurred after the balance sheet date, but before the consolidated financial statements are issued. Subsequent to June 30, 2019, the Company issued 89,981 shares of common stock as payment of approximately $2.0 million in other current liabilities.

NOTE 20 - REVISION

NOTE 20 - REVISION	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
NOTE 20 - REVISION	FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019, 2018 and 2017 NOTE 20 - REVISION The Company is restating its previously issued Consolidated balance sheets and Consolidated statements of cash flows as of and for the nine month interim periods of fiscal 2019 ended March 31, 2019 to reflect a revision in presentation of short term investments within current assets. In the aforementioned financial statements, the Company presented certain Certificates of Deposit with financial institutions (“CDs”) with maturities greater than three months as Cash and cash equivalents, when they should have been presents as Short-term investments. This misclassification did not impact Revenue, Operating income, Net income, Total assets or Total current assets. The following tables summarizes the impacts of these misclassifications on the consolidated balance sheets and statements of cash flows for the interim periods of fiscal 2019 (amount in thousands): As of March 31, 2019 ((Unaudited) Financial Statement Captions Revised As Previously Reported Adjustment As Restated Cash and cash equivalents $ 24,780 $ (15,000 ) $ 9,780 Short-term investments $ 0 $ 15,000 $ 15,000 For the Nine Months ended March 31, 2019 (Unaudited) As Previously Reported Adjustment As Restated Statement of Cash Flows Captions Revised Cash Flows from Investing Activities $ (3,157 ) $ (15,000 ) $ (18,157 ) Cash and cash equivalents - end of period $ 24,780 $ (15,000 ) $ 9,780

NOTE 2 - SUMMARY OF SIGNIFICA_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships. The operating activities of subsidiaries are included in the accompanying consolidated statements from the date of acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The most significant estimates relate to receivable allowances, intangible assets, income taxes and related tax asset valuation allowances, useful lives of property and equipment, contingencies, revenue recognition and the assessment of litigation. In addition, healthcare industry reforms and reimbursement practices will continue to impact the Company's operations and the determination of contractual and other allowance estimates. Actual results could differ from those estimates.
Inventories	Inventories Inventories consist of purchased parts, components and supplies, as well as work-in-process, and are stated at the lower of cost, determined on the first-in, first-out method, or market.
Property and Equipment	Property and Equipment Property and equipment procured in the normal course of business is stated at cost. Property and equipment purchased in connection with an acquisition is stated at its estimated fair value, generally based on an appraisal. Property and equipment is being depreciated for financial accounting purposes using the straight-line method over their estimated useful lives. Leasehold improvements are being amortized over the shorter of the useful life or the remaining lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gains or losses are reflected in the results of operations. Expenses for maintenance and repairs are charged to operations. Renewals and betterments are capitalized. Maintenance and repair expenses totaled approximately $1,557,000, $1,451,000 and $1,116,000 for the years ended June 30, 2019, 2018 and 2017, respectively. The estimated useful lives in years are generally as follows: Diagnostic equipment 5–13 Research, development and demonstration equipment 3-7 Machinery and equipment 2-7 Furniture and fixtures 3-9 Leasehold improvements 2–10 Building 28
Long-Lived Assets	Long-Lived Assets The Company periodically assesses the recoverability of long-lived assets, including property and equipment and intangibles, other than goodwill, when there are indications of potential impairment, based on estimates of undiscounted future cash flows. The amount of impairment is calculated by comparing anticipated discounted future cash flows with the carrying value of the related asset. In performing this analysis, management considers such factors as current results, trends, and future prospects, in addition to other economic factors.
Deferred Rent	Deferred Rent Rent expense is recorded on the straight-line method based on the total minimum rent payments required over the term of the lease. The cumulative difference between the lease expense recorded under this method and the contractual lease payment terms is recorded as deferred rent.
Other Intangible Assets	Other Intangible Assets 1) Capitalized Software Development Costs Capitalization of software development costs begins upon the establishment of technological feasibility. Technological feasibility for the Company’s computer software is generally based upon achievement of a detail program design free of high risk development issues and the completion of research and development on the product hardware in which it is to be used. The establishment of technological feasibility and the ongoing assessment of recoverability of capitalized computer software development costs require considerable judgment by management with respect to certain external factors, including, but not limited to, technological feasibility, anticipated future gross revenue, estimated economic life and changes in software and hardware technology. Prior to reaching technological feasibility those costs are expensed as incurred and included in research and development. Amortization of capitalized software development costs commences when the related products become available for general release to customers. Amortization is provided on a product by product basis. The annual amortization is the greater of the amount computed using (a) the ratio that current gross revenue for a product bears to the total of current and anticipated future gross revenue for that product, or (b) the straight-line method over the remaining estimated economic life of the product. The Company periodically performs reviews of the recoverability of such capitalized software development costs. At the time a determination is made that capitalized amounts are not recoverable, based on the estimated cash flows to be generated from the applicable software, any remaining capitalized amounts are written off. 2) Patents and Copyrights Amortization is calculated on the straight-line basis over 15 years. 3) Non-Competition Agreements The non-competition agreements are being amortized on the straight line basis over the length of the agreement (7 years). 4) Customer Relationships Amortization is calculated on the straight line basis over 20 years.
Goodwill	Goodwill Generally accepted accounting principles in the United States require the Company to perform a goodwill impairment test annually and more frequently when negative conditions or a triggering event arises. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit’s carrying amount, including goodwill to the fair value of the reporting unit. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered potentially impaired and a second step is performed to measure the amount of impairment loss, if any.
Acquired Assets and Assumed Liabilities	Acquired assets and assumed liabilities Pursuant to ASC No. 805-10-25, if the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, but during the allowed measurement period not to exceed one year from the acquisition date, the Company adjusts the provisional amounts recognized at the acquisition date by means of adjusting the amount recognized for goodwill.
Revenue Recognition	Revenue Recognition Revenue on sales contracts for scanners, included in “product sales” in the accompanying consolidated statements of operations, is recognized under the percentage-of-completion method in accordance with FASB ASC 605-35, “Revenue Recognition – Construction-Type and Production-Type Contracts”. The Company manufactures its scanners under specific contracts that provide for progress payments. Production and installation take approximately three to six months. Revenue on scanner service contracts is recognized on the straight-line method over the related contract period, usually one year. Revenue from product sales (upgrades and supplies) is recognized upon shipment. Revenue under management contracts is recognized based upon contractual agreements for management services rendered by the Company primarily under various long-term agreements with various medical providers (the "PCs"). As of June 30, 2019, the Company has twenty two management agreements of which three are with PC’s owned by Raymond V. Damadian, M.D., Chairman of the Board of FONAR (“the Related medical practices”) and nineteen are with PC’s, which are all located in the state of New York (“the New York PC’s”), owned by two unrelated radiologists. The contractual fees for services rendered to the PCs consists of fixed monthly fees per diagnostic imaging facility ranging from approximately $54,000 to $481,000. All fees are re-negotiable at the anniversary of the agreements and each year thereafter. The Company records a provision for bad debts for estimated uncollectible fees, which is reflected in other operating expenses on the Statement of Operations. Revenue under lease contracts is recognized based upon contractual agreements for the leasing of medical equipment primarily under long term contracts to various unrelated PC’s. All fees are re-negotiable at the anniversary of the agreements and each year thereafter. On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue. The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2019. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Additionally, upon adoption of ASC 606 the allowance for doubtful accounts of approximately $22.7 million as of July 1, 2018 was reclassified as a component of net patient accounts receivable. Other than these changes in presentation on the condensed consolidated statement of operations and condensed consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated results of operations for the year ended June 30, 2019 and is not expected to have a material impact on its consolidated results of operations on a prospective basis. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenues, net of contractual allowances and discounts less the provision for bad debts for the years ended June 30, 2019, 2018 and 2017 are summarized in the following table. For the Year Ended June 30, 2019 2018 2017 Commercial Insurance/ Managed Care $ 5,218,656 $ 4,729,514 $ 4,904,892 Medicare/Medicaid 1,172,543 1,233,078 1,274,436 Workers' Compensation/Personal Injury 16,790,025 25,358,543 23,240,829 Other 1,026,312 7,844,278 6,980,443 Patient Fee Revenue, net of contractual allowances and discounts 24,207,536 39,165,413 36,400,600 Provision for Bad Debts — (17,896,528 ) (16,171,434 ) Net Patient Fee Revenue $ 24,207,536 $ 21,268,885 $ 20,229,166
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred. The costs of equipment that are acquired or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. Advertising expense approximated $538,000, $607,000 and $531,000 for the years ended June 30, 2019, 2018 and 2017, respectively.
Shipping Costs	Shipping Costs The Company’s shipping and handling costs are included in revenue from product sales and the related expense included in costs related to product sales is $13,695, $9,370 and $8,224 for the years ended June 30, 2019, 2018 and 2017, respectively.
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse.
Customer Advances	Customer Advances Cash advances and progress payments received on sales orders are reflected as customer advances until such time as revenue recognition occurs.
Earnings Per Share	Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class Method”, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share for the years ended June 30, 2019, 2018 and 2017. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the years ended June 30, 2019, 2018 and 2017, diluted EPS for common shareholders includes 127,504 shares upon conversion of Class C Common. June 30, 2019 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 12,025,078 $ 11,278,997 $ 190,012 Denominator: Weighted average shares outstanding 6,354,103 6,354,103 382,513 Basic income per common share $ 1.89 $ 1.78 $ 0.50 Diluted Denominator: Weighted average shares outstanding 6,354,103 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,481,607 382,513 Diluted income per common share $ 1.74 $ 0.50 June 30, 2018 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 21,230,802 $ 19,899,823 $ 338,974 Denominator: Weighted average shares outstanding 6,287,510 6,287,510 382,513 Basic income per common share $ 3.38 $ 3.16 $ 0.89 Diluted Denominator: Weighted average shares outstanding 6,287,510 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,415,014 382,513 Diluted income per common share $ 3.10 $ 0.89 June 30, 2017 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 19,620,621 $ 18,390,586 $ 313,266 Denominator: Weighted average shares outstanding 6,161,599 6,161,599 382,513 Basic income per common share $ 3.18 $ 2.98 $ 0.82 Diluted Denominator: Weighted average shares outstanding 6,161,599 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,289,103 382,513 Diluted income per common share $ 2.92 $ 0.82
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents includes cash on hand, cash in banks, investments in certificates of deposit with original maturities of 90 days or less, and money market funds.
Short Term Investments	Short term investments Short term investments include certificates of deposit with original maturities of greater than 90 days.
Concentration of Credit Risk	Concentration of Credit Risk Cash: The Company maintains its cash and cash equivalents with various financial institutions, which exceed federally insured limits throughout the year. At June 30, 2019, the Company had cash on deposit of approximately $11,842,000 in excess of federally insured limits of $250,000. Related Parties: Net revenues from related parties accounted for approximately 11%, 11% and 11% of the consolidated net revenues for the years ended June 30, 2019, 2018 and 2017, respectively. Net management fee receivables from the related party medical practices accounted for approximately 13%, 12% and 13% of the consolidated accounts receivable for the years ended June 30, 2019, 2018 and 2017, respectively. See Note 3 regarding the Company’s concentrations in the healthcare industry.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The financial statements include various estimated fair value information at June 30, 2019 and 2018, as required by ASC topic 820, "Disclosures about Fair Value of Financial Instruments". Such information, which pertains to the Company's financial instruments, is based on the requirements set forth in that Statement and does not purport to represent the aggregate net fair value to the Company. The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value: Cash and cash equivalents: The carrying amount approximates fair value because of the short-term maturity of those instruments. Receivable and accounts payable: The carrying amounts approximate fair value because of the short maturity of those instruments. Short term investments: The carrying amount approximates fair value because of the short-term maturity of those instruments. Notes receivable: The carrying amount approximates fair value because the discounted present value of the cash flow generated by the parties approximates the carrying value of the amounts due to the Company. Long-term debt and notes payable: The carrying amounts of debt and notes payable approximate fair value due to the length of the maturities, the interest rates being tied to market indices and/or due to the interest rates not being significantly different from the current market rates available to the Company. All of the Company's financial instruments are held for purposes other than trading.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled in exchange for goods and services as it transfers control to its customers. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The Company earns revenue from the sale of scanners, maintenance contracts, product upgrades, patient services and management fees. Under the new guidance, the reporting for patient services revenue will be reported differently. All other streams of revenue will not be impacted by the new guidance. The primary change for healthcare providers under the new guidance relates to revenue generated from patient services, with patient responsibility for payment. Under the new guidance, the Company is required to report an implicit price concession (both initially and for the subsequent changes in estimates) as a reduction of revenues as opposed to bad debt expense as a component of operating expenses. The Company will record any changes in expectation of collection amounts due to patient specific events that suggests that the patient no longer has the ability and intent to pay the amount due through the bad debt expense, as that is more indicative of a change in the customer’s credit worthiness as opposed to change in the transaction price. The new standard supersedes most current revenue guidance, including industry-specific guidance. The guidance became effective for the Company on July 1, 2018 and as part of adopting the standard, the Company identified revenue streams of like contracts to allow for ease of implementation. The Company used primarily a portfolio approach to apply the new model to classes of customers with similar characteristics. The impact of adopting the new standard on our total revenue; and income from operations is not material. While the adoption of ASU 2014-09 will impact the presentation of net operating revenues in our Consolidated Statements of Operations and will impact certain disclosures, it will not materially impact our financial position, results of operations or cash flows. There was no cumulative effect of a change in accounting principle recorded related to the adoption of ASU 2014-09 on July 1, 2018. In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company has adopted this guidance on our Consolidated Financial Statements and it has no impact on the Company’s financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases Leases Targeted Improvements FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of June 30, 2019 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2019 or 2018, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported net income for any periods presented.

NOTE 2 - SUMMARY OF SIGNIFICA_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Estimated Useful Life in Years for Property and Equipment	The estimated useful lives in years of property and equipment are generally as follows: Diagnostic equipment 5–13 Research, development and demonstration equipment 3-7 Machinery and equipment 2-7 Furniture and fixtures 3-9 Leasehold improvements 2–10 Building 28
Patient Fee Revenue - Net	The Company’s patient fee revenues, net of contractual allowances and discounts less the provision for bad debts for the years ended June 30, 2019, 2018 and 2017 are summarized in the following table: For the Year Ended June 30, 2019 2018 2017 Commercial Insurance/ Managed Care $ 5,218,656 $ 4,729,514 $ 4,904,892 Medicare/Medicaid 1,172,543 1,233,078 1,274,436 Workers' Compensation/Personal Injury 16,790,025 25,358,543 23,240,829 Other 1,026,312 7,844,278 6,980,443 Patient Fee Revenue, net of contractual allowances and discounts 24,207,536 39,165,413 36,400,600 Provision for Bad Debts — (17,896,528 ) (16,171,434 ) Net Patient Fee Revenue $ 24,207,536 $ 21,268,885 $ 20,229,166
Earnings Per Share	Basic earnings per share (“EPS”) is computed by dividing net income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the years ended June 30, 2019, 2018 and 2017, diluted EPS for common shareholders includes 127,504 shares upon conversion of Class C Common. June 30, 2019 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 15,317,131 $ 14,366,798 $ 242,031 Denominator: Weighted average shares outstanding 6,354,103 6,354,103 382,513 Basic income per common share $ 2.41 $ 2.26 $ 0.63 Diluted Denominator: Weighted average shares outstanding 6,354,103 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,481,607 382,513 Diluted income per common share $ 2.22 $ 0.63 June 30, 2018 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 21,230,802 $ 19,899,823 $ 338,974 Denominator: Weighted average shares outstanding 6,287,510 6,287,510 382,513 Basic income per common share $ 3.38 $ 3.16 $ 0.89 Diluted Denominator: Weighted average shares outstanding 6,287,510 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,415,014 382,513 Diluted income per common share $ 3.10 $ 0.89 June 30, 2017 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 19,620,621 $ 18,390,586 $ 313,266 Denominator: Weighted average shares outstanding 6,161,599 6,161,599 382,513 Basic income per common share $ 3.18 $ 2.98 $ 0.82 Diluted Denominator: Weighted average shares outstanding 6,161,599 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,289,103 382,513 Diluted income per common share $ 2.92 $ 0.82

NOTE 3 - ACCOUNTS RECEIVABLE,_2

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Total Facilities	The following table sets forth the number of scanning center facilities for the years ended June 30, 2019, 2018 and 2017: For The Year Ended June 30, 2019 2018 2017 Total Facilities Owned or Managed (at Beginning of Year) 26 26 25 Facilities Added by: Acquisition — — 1 Internal development — — — Managed Facilities Closed — — — Total Facilities Owned or Managed (at End of Year) 26 26 26

NOTE 4 - COSTS AND ESTIMATED _2

NOTE 4 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables)	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Costs and Estimated Earnings on Uncompleted Contracts	Information relating to uncompleted contracts as of June 30, 2019 and 2018 is as follows: As of June 30, 2019 2018 Costs incurred on uncompleted contracts $ 448,437 $ 448,437 Estimated earnings 1,088,675 309,248 1,537,112 757,685 Less: Billings to date 1,012,002 671,047 $ 525,110 $ 86,638

NOTE 5 - INVENTORIES (Tables)

NOTE 5 - INVENTORIES (Tables)	12 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories included in the accompanying consolidated balance sheets consist of: As of June 30, 2019 2018 Purchased parts, components and supplies $ 1,639,777 $ 1,312,299 Work-in-process 158,389 119,081 $ 1,798,166 $ 1,431,380

NOTE 6 - PROPERTY AND EQUIPME_2

NOTE 6 - PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment, at cost, less accumulated depreciation and amortization, at June 30, 2019 and 2018, is comprised of: As of June 30, 2019 2018 Diagnostic equipment $ 26,090,218 $ 24,296,957 Research, development and demonstration equipment 3,605,906 2,987,531 Machinery and equipment 2,069,055 2,069,055 Furniture and fixtures 3,122,102 3,036,539 Leasehold improvements 8,023,292 7,165,035 Building 939,614 939,614 43,850,187 40,494,731 Less: Accumulated depreciation and amortization 26,864,570 24,002,453 $ 16,985,617 $ 16,492,278

NOTE 7 - OTHER INTANGIBLE ASS_2

NOTE 7 - OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intagible Assets - Net	Other intangible assets, net of accumulated amortization, at June 30, 2019 and 2018 are comprised of: As of June 30, 2019 2018 Capitalized software development costs $ 7,004,847 $ 7,004,847 Patents and copyrights 4,964,199 4,835,806 Non-competition agreements 4,100,000 4,100,000 Customer relationships 3,800,000 3,800,000 19,869,046 19,740,653 Less: Accumulated amortization 15,113,371 14,138,997 $ 4,755,675 $ 5,601,656
Schedule Of Other Intangle Assets	The estimated amortization of other intangible assets for the five years ending June 30, 2024 and thereafter is as follows: For the Years Ending June 30, Total Patents and Copyrights Non- Customer Relationships 2020 $ 771,830 $ 191,353 $ 390,477 $ 190,000 2021 381,860 191,860 — 190,000 2022 380,470 190,470 — 190,000 2023 383,929 193,929 — 190,000 2024 375,561 185,561 — 190,000 Thereafter 2,462,025 815,358 — 1,646,667 $ 4,755,675 $ 1,768,531 $ 390,477 $ 2,596,667
Amortization of Other Intangible Assets	Information related to the other intangible assets for the years ended June 30, 2019, 2018 and 2017 is as follows: As of June 30, 2019 2018 2017 Balance – Beginning of Year $ 5,601,656 $ 6,644,504 $ 7,719,358 Amounts capitalized 128,393 108,829 155,156 Software or patents written off — — — ) Amortization (974,374 ) (1,151,677 ) (1,230,010 ) Balance – End of Year $ 4,755,675 $ 5,601,656 $ 6,644,504

NOTE 9 - CONTROLLING AND NONC_2

NOTE 9 - CONTROLLING AND NONCONTROLLING INTERESTS (Tables)	12 Months Ended
	Jun. 30, 2019
Noncontrolling Interest [Abstract]
Class A And B Members' Equity (HDM Acquisition)	Amount of each class of HDM members’ equity, as of June 30, 2019, 2018 and 2017, is as follows: June 30, 2019 June 30, 2018 June 30, 2017 Class A Members Class B Member Class A Members Class B Member Class A Members Class B Member Opening Members’ Equity $ 3,559,182 $ 31,775,922 $ 5,472,799 $ 27,988,982 $ 8,396,575 $ 23,314,842 Share of Net Income 5,196,543 20,167,864 4,221,383 18,101,940 4,058,177 16,947,624 Distributions (6,600,000 ) (15,400,000 ) (6,135,000 ) (14,315,000 ) (6,981,953 ) (12,273,484 ) Ending Members’ Equity $ 2,155,725 $ 36,543,786 $ 3,559,182 $ 31,775,922 $ 5,472,799 $ 27,988,982

NOTE 10 - LONG-TERM DEBT, NOT_2

NOTE 10 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES (Tables)	12 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Long-Term Debt, Notes Payable And Capital Leases	Long-term debt, notes payable and capital leases consist of the following: 2019 2018 Note payable requiring monthly payments of interest at a rate of 7% until May 2009 followed by 240 monthly payments of $4,472 through October 2026. The loan is collateralized by a building with a net book value of $481,666 as of June 30, 2019. $ 306,056 $ 336,781 The revolving credit note was extended to August 2020. The Company can prepay the loan in whole or part in multiples of $100,000 at any time without penalty. The note bears interest at a rate of 5.25% per annum and is payable monthly. The loan is collateralized by substantially all of the Company’s assets. The loan also contains certain financial covenants that must be met on a periodic basis. The note was paid in full September 2, 2014. The Company still has the ability to draw down on the line. — — Other (including capital leases for property and equipment). 7,586 7,586 313,642 344,367 Less: Current portion 40,530 38,332 $ 273,112 $ 306,035
Maturities Of Long-Term Debt	The maturities of long-term debt over the next five years and thereafter are as follows: Years Ending June 30, 2020 $ 40,530 2021 35,416 2022 38,013 2023 40,820 2024 43,767 Thereafter 115,096 $ 313,642

NOTE 11 - INCOME TAXES (Tables)

NOTE 11 - INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Components Of The Benefit Provision For Income Taxes	Components of the provision (benefit) for income taxes are as follows: Years Ended June 30, 2019 2018 2017 Current: Federal $ — $ 185,000 $ 250,000 State 250,000 265,000 357,235 Subtotal 250,000 450,000 607,235 Deferred: Federal deferred taxes 1,685,299 (4,132,590 ) (4,552,702 ) State deferred taxes 70,221 (787,160 ) (416,967 ) AMT Credits — (1,200,000 ) — Subtotal 1,755,520 (6,119,750 ) (4,969,669 ) $ 2,005,520 $ (5,669,750 ) $ (4,362,434 )
Reconciliation Of Federal Statutory Income Tax Rate To Company's Effective Tax Rate	A reconciliation of the federal statutory income tax rate to the Company's effective tax rate as reported is as follows: Years Ended June 30, 2019 2018 2017 Taxes at federal statutory rate 21.0 % 27.7 % 35.0 % State and local income taxes (benefit), net of federal benefit 4.0 % 4.0 % 4.0 % Non Controlling interest (5.8 )% (6.8 )% (8.2 )% Permanent differences (3.5 )% 0.1 % 0.1 % Tax Cuts and Jobs Act Rate Change 0 % (26.9 )% 0 % Decrease in the valuation allowance (2.6 )% (18.5 )% (55.7 )% AMT Credits 0 % (6.4 )% 0 % Other (4.2 )% (1.8 )% 2.2 % Effective income tax rate 8.9 % (28.6 )% (22.6 )%
Components Of Company's Deferred Tax Assets And Liabilities	Significant components of the Company's deferred tax assets and liabilities at June 30, 2019 and 2018 are as follows: June 30, 2019 2018 Deferred tax assets: Allowance for doubtful accounts $ 3,011,480 $ 3,262,504 Non-deductible accruals 861,345 752,595 Net operating carryforwards 16,448,054 20,665,597 Tax credits 4,601,801 4,330,769 Inventory 65,081 55,514 Property and equipment and depreciation 192,133 213,781 25,179,894 29,280,760 Valuation allowance (4,242,147 ) (6,591,749 ) Total deferred tax assets 20,937,747 22,689,011 Intangibles (243,267 ) (239,011 ) Total deferred tax liabilities (243,267 ) (239,011 ) Net deferred tax asset $ 20,694,480 $ 22,450,000

NOTE 12 - OTHER CURRENT LIABI_2

NOTE 12 - OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Other Current Liabilities	Included in other current liabilities are the following: June 30, 2019 2018 Accrued salaries, commissions and payroll taxes $ 3,897,833 $ 3,438,087 Litigation accruals 145,029 145,029 Sales tax payable 1,671,488 2,092,403 Legal and other professional fees 125,567 119,262 Accounting fees 105,000 125,000 Self-funded health insurance reserve 67,825 79,129 Accrued interest and penalty 1,054,134 1,497,429 Other 510,540 681,656 $ 7,577,416 $ 8,177,995

NOTE 13 - COMMITMENTS AND CON_2

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Operating Lease Commitments	Future minimum operating lease commitments consisted of the following at June 30, 2019: Year Ending Facilities And Equipment 2020 $ 4,655,396 2021 4,323,037 2022 3,396,273 2023 2,778,617 2024 2,350,193 Thereafter 5,081,636 Total minimum obligations $ 22,585,152

NOTE 16 - SEGMENT AND RELATED_2

NOTE 16 - SEGMENT AND RELATED INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Summarized Segment Financial Information	Summarized financial information concerning the Company’s reportable segments is shown in the following table: Manufacturing and Servicing of Medical Management of Diagnostic Imaging Fiscal 2019: Equipment Center Totals Net revenues from external customers $ 10,013,394 $ 77,179,493 $ 87,192,887 Intersegment net revenues * $ 907,084 $ — $ 907,084 (Loss) Income from operations $ (3,419,944 ) $ 25,554,136 $ 22,134,192 Depreciation and amortization $ 370,001 $ 3,466,490 $ 3,836,491 Compensatory element of stock issuances $ 1,990,380 $ — $ 1,990,380 Total identifiable assets $ 25,065,808 $ 105,198,093 $ 130,263,901 Capital expenditures $ 746,768 $ 2,737,081 $ 3,483,849 Fiscal 2018: Net revenues from external customers $ 9,837,269 $ 71,678,725 $ 81,515,994 Intersegment net revenues * $ 901,250 $ — $ 901,250 (Loss) Income from operations $ (2,982,778 ) $ 22,666,989 $ 19,684,211 Depreciation and amortization $ 353,307 $ 3,546,544 $ 3,899,851 Compensatory element of stock issuances $ 1,954,744 $ — $ 1,954,744 Total identifiable assets $ 32,364,298 $ 85,946,647 $ 118,310,945 Capital expenditures $ 346,608 $ 2,540,169 $ 2,886,777 Fiscal 2017: Net revenues from external customers $ 11,219,188 $ 66,817,398 $ 78,036,586 Intersegment net revenues * $ 1,200,000 $ — $ 1,200,000 (Loss) Income from operations $ (2,292,312 ) $ 21,388,392 $ 19,096,080 Depreciation and amortization $ 324,550 $ 3,209,014 $ 3,533,564 Compensatory element of stock issuances $ 2,397,276 $ — $ 2,397,276 Total identifiable assets $ 29,103,809 $ 69,658,676 $ 98,762,566 Capital expenditures $ 212,983 $ 2,793,331 $ 3,006,314 * Amounts eliminated in consolidation
Export Product Sales	The foreign product sales, as a percentage of product sales to unrelated parties, were made to customers in the following countries: For the Years Ended June 30, 2019 2018 2017 United Arab Emirates — % 7.1 % 45.4 % Canada .3 — — England .3 29.9 4.8 Germany — 4.5 — Puerto Rico 4.7 — 5.7 5.3 % 41.5 % 55.9 %
Foreign Service and Repair Fees	Foreign service and repair fees, as a percentage of total service and repair fees, were provided principally to the following countries: For the Years Ended June 30, 2019 2018 2017 Puerto Rico 1.6 % 1.5 % 1.2 % Switzerland 0.3 0.2 0.2 Germany 1.4 1.3 1.4 England 0.6 0.6 0.5 United Arab Emirates 0.3 0.3 — Canada 0.4 — 0.1 Greece 0.3 0.2 0.2 Australia 1.0 0.9 1.0 5.9 % 5.0 % 4.6 %

NOTE 17 - ALLOWANCE FOR DOUBT_2

NOTE 17 - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Tables)	12 Months Ended
	Jun. 30, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Summary of Allowance For Doubtful Accounts	The following represents a summary of allowance for doubtful accounts for the years ended June 30, 2019, 2018 and 2017, respectively: Description Balance Additions (1) Deductions Balance Accounts receivable $ 190,244 $ — $ — $ 190,244 Management and other fees receivable 10,983,022 (1,578,078 ) — 9,404,944 Management and other fees receivable - related medical practices 1,711,385 599,346 — 2,310,731 Medical receivables 22,727,698 — 22,727,698 — Description Balance June 30, 2017 Additions Deductions Balance June 30, 2018 Accounts receivables $ 190,244 $ — $ — $ 190,244 Management and other fees receivable 12,859,750 (1,744,064 ) 132,664 10,983,022 Management and other fees receivable - related medical practices 582,001 1,129,384 — 1,711,385 Medical receivables 19,853,318 17,896,528 15,022,148 22,727,698 Description Balance June 30, 2016 Additions Deductions Balance June 30, 2017 Accounts receivables $ 284,279 $ — $ 94,035 $ 190,244 Management and other fees receivable 13,553,005 (104,424 588,831 12,859,750 Management and other fees receivable - related medical practices 392,505 582,001 392,505 582,001 Medical receivables 17,451,782 16,171,434 12,547,160 19,853,318 (1) Included in provision for bad debts.

NOTE 18 - QUARTERLY FINANCIAL_2

NOTE 18 - QUARTERLY FINANCIAL DATA (Tables)	12 Months Ended
	Jun. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Quarterly Financial Data	Quarterly financial data (Unaudited) (000’s omitted, except per share data) September 30, 2018 December 31, 2018 March 31, 2019 June 30, 2019 Total Total Revenues – Net $ 20,705 $ 21,225 $ 22,779 $ 22,484 $ 87,193 Total Costs and Expenses 15,163 15,245 16,171 18,480 65,059 Net Income 4,492 4,864 5,201 2,665 17,222 Basic Net Income Per Common Share Available to Common Stockholders $ 0.49 $ 0.52 $ 0.57 $ 0.20 $ 1.78 Diluted Net Income Per Common Share Available to Common Stockholders $ 0.48 $ 0.51 $ 0.56 $ 0.19 $ 1.74 September 30, 2017 December 31, 2017 March 31, 2018 June 30, 2018 Total Total Revenues – Net $ 19,334 $ 20,168 $ 20,979 $ 21,035 $ 81,516 Total Costs and Expenses 14,549 14,358 16,577 16,348 61,832 Net Income 4,601 5,240 4,262 11,349 25,452 Basic Net Income Per Common Share Available to Common Stockholders $ 0.55 $ 0.62 $ 0.52 $ 1.47 $ 3.16 Diluted Net Income Per Common Share Available to Common Stockholders $ 0.54 $ 0.61 $ 0.51 $ 1.44 $ 3.10

NOTE 19 - BUSINESS COMBINATIO_2

NOTE 19 - BUSINESS COMBINATIONS (Tables)	12 Months Ended
	Jun. 30, 2019
Turnkey Equipment Management of Great Neck, LLC
Acquisition	On June 15, 2017, the Company purchased 100% interest in Turnkey Equipment Management of Great Neck, LLC. The consideration and net assets acquired is as follows: Cash Paid $ 1,312,769 Security deposit 23,775 Total Consideration 1,336,544 Net assets at Fair Value 731,582 Goodwill $ 604,962
Radwell Leasing, LLC & Radwell LLC
Acquisition	On March 20, 2017, the Company purchased 100% interest in Radwell Leasing LLC and Radwell LLC. The net assets acquired and consideration is as follows: Diagnostic Equipment $ 544,375 Leasehold Improvements 126,237 Total Net Assets Acquired $ 670,612 Stock issued as consideration $ 791,210 Less cash received - Net (120,598 ) Total Consideration $ 670,612

NOTE 20 - REVISION (Tables)

NOTE 20 - REVISION (Tables)	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Statement of Cash Flows Captions - Revised	The following tables summarizes the impacts of these misclassifications on the consolidated balance sheets and statements of cash flows for the interim periods of fiscal 2019 (amount in thousands): As of March 31, 2019 ((Unaudited) Financial Statement Captions Revised As Previously Reported Adjustment As Restated Cash and cash equivalents $ 24,780 $ (15,000 ) $ 9,780 Short-term investments $ 0 $ 15,000 $ 15,000 For the Nine Months ended March 31, 2019 (Unaudited) As Previously Reported Adjustment As Restated Statement of Cash Flows Captions Revised Cash Flows from Investing Activities $ (3,157 ) $ (15,000 ) $ (18,157 ) Cash and cash equivalents - end of period $ 24,780 $ (15,000 ) $ 9,780

NOTE 2 - SUMMARY OF SIGNIFICA_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful Life in Years - (Details)	12 Months Ended
	Jun. 30, 2019
Diagnostic Equipment | Minimum
Property, Plant and Equipment	5 years
Diagnostic Equipment | Maximum
Property, Plant and Equipment	13 years
Research, Development, and Demonstration Equipment | Minimum
Property, Plant and Equipment	3 years
Research, Development, and Demonstration Equipment | Maximum
Property, Plant and Equipment	7 years
Machinery and Equipment | Minimum
Property, Plant and Equipment	2 years
Machinery and Equipment | Maximum
Property, Plant and Equipment	7 years
Furniture and Fixtures | Minimum
Property, Plant and Equipment	3 years
Furniture and Fixtures | Maximum
Property, Plant and Equipment	9 years
Leasehold Improvements | Minimum
Property, Plant and Equipment	2 years
Leasehold Improvements | Maximum
Property, Plant and Equipment	10 years
Building | Weighted Average
Property, Plant and Equipment	28 years

NOTE 2 - SUMMARY OF SIGNIFICA_5

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Fee Revenue Recognition - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Patient fee revenue, net of contractual allowances and discounts	$ 24,207,536	$ 39,165,413	$ 36,400,600
Less: Patient Fee Revenue Provision for Bad Debts		(17,896,528)	(16,171,434)
Net Patient Fee Revenue	24,207,536	21,268,885	20,229,166
Commercial Insurance / Managed Care
Patient fee revenue, net of contractual allowances and discounts	5,218,656	4,729,514	4,904,892
Medicare/Medicaid
Patient fee revenue, net of contractual allowances and discounts	1,172,543	1,233,078	1,274,436
Workers Compensation/Personal Injury
Patient fee revenue, net of contractual allowances and discounts	16,790,025	25,358,543	23,240,829
Other Patient Fee Revenues
Patient fee revenue, net of contractual allowances and discounts	$ 1,026,312	$ 7,844,278	$ 6,980,443

NOTE 2 - SUMMARY OF SIGNIFICA_6

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Basic Numerator: Net Income Available to Common Stockholders	$ 15,317,131	$ 21,230,802	$ 19,620,621
Common Shares
Basic Numerator: Net Income Available to Common Stockholders	$ 14,366,798	$ 19,899,823	$ 18,390,586
Basic Denominator: Weighted Average Shares Outstanding	6,354,103	6,287,510	6,161,599
Basic Income Per Common Share	$ 2.26	$ 3.16	$ 2.98
Shares included upon conversion of Class C Common to calculate a diluted EPS	127,504	127,504	127,504
Total Denominator for Diluted Earnings Per Share	6,481,607	6,415,014	6,289,103
Diluted Income per Common Share	$ 2.22	$ 3.1	$ 2.92
Class C Common Stock
Basic Numerator: Net Income Available to Common Stockholders	$ 242,031	$ 338,974	$ 313,266
Basic Denominator: Weighted Average Shares Outstanding	382,513	382,513	382,513
Basic Income Per Common Share	$ 0.63	$ 0.89	$ 0.82
Shares included upon conversion of Class C Common to calculate a diluted EPS
Total Denominator for Diluted Earnings Per Share	382,513	382,513	382,513
Diluted Income per Common Share	$ 0.63	$ 0.89	$ 0.82
Total
Basic Numerator: Net Income Available to Common Stockholders	$ 15,317,131	$ 21,230,802	$ 19,620,621
Basic Denominator: Weighted Average Shares Outstanding	6,354,103	6,287,510	6,161,599
Basic Income Per Common Share	$ 2.41	$ 3	$ 3.18

NOTE 3 - ACCOUNTS RECEIVABLE,_3

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE-Total Facilities (Details)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Note 3 - Accounts Receivable Medical Receivable And Management And Other Fees Receivable-total Facilities
Total Facilities Owned or Managed (at Beginning of Year)	26	26	25
Managed Facilities Added Acquisition	0	0	1
Managed Facilities Added By Internal development	0	0	0
Managed Facilities Closed During year	0	0	0
Total Facilities Owned or Managed (at End of Year)	26	26	26

NOTE 4 - COSTS AND ESTIMATED _3

NOTE 4 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Costs, Earnings, Billings, Uncompleted Contracts - (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Notes to Financial Statements
Costs incurred on uncompleted contracts	$ 448,437	$ 448,437
Estimated earnings	1,088,675	309,248
Costs and estimated earnings on uncompleted contracts	1,537,112	757,685
Less: Billings to date	1,012,002	671,047
Costs and estimated earnings in excess of billings on uncompleted contracts	$ 525,110	$ 86,638

NOTE 5 - INVENTORIES - Inventor

NOTE 5 - INVENTORIES - Inventories (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Inventory Disclosure [Abstract]
Purchased parts, components and supplies	$ 1,639,777	$ 1,312,299
Work-in-process	158,389	119,081
Inventories	$ 1,798,166	$ 1,431,380

NOTE 6 - PROPERTY AND EQUIPME_3

NOTE 6 - PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Property and Equipment Before Accumulated depreciation and amortization	$ 43,850,187	$ 40,494,731
Less: Accumulated depreciation and amortization of property and equipment	26,864,570	24,002,453
Property and Equipment AfterAccumulated depreciation and amortization	16,985,617	16,492,278
Diagnostic Equipment
Property and Equipment Before Accumulated depreciation and amortization	26,090,218	24,296,957
Research, development and demonstration equipment
Property and Equipment Before Accumulated depreciation and amortization	3,605,906	2,987,531
Machinery and Equipment
Property and Equipment Before Accumulated depreciation and amortization	2,069,055	2,069,055
Furniture and Fixtures
Property and Equipment Before Accumulated depreciation and amortization	3,122,102	3,036,539
Leasehold Improvements
Property and Equipment Before Accumulated depreciation and amortization	8,023,292	7,165,035
Building
Property and Equipment Before Accumulated depreciation and amortization	$ 939,614	$ 939,614

NOTE 7 - OTHER INTANGIBLE ASS_3

NOTE 7 - OTHER INTANGIBLE ASSETS - Other Intagible Assets Net of Amoritization (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalized software development costs	$ 7,004,847	$ 7,004,847
Patents and copyrights	4,964,199	4,835,806
Non-competition agreements	4,100,000	4,100,000
Customer Relationships	3,800,000	3,800,000
Less: Accumulated amortization	15,113,371	14,138,997
Other intangible assets - net	$ 4,755,675	$ 5,601,656

NOTE 7 - OTHER INTANGIBLE ASS_4

NOTE 7 - OTHER INTANGIBLE ASSETS - Schedule Of Intangle Assets - (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Balance - Beginning of Year	$ 5,601,656	$ 6,644,504	$ 7,719,358
Amounts capitalized	128,393	108,829	155,156
Software or patents written off
Amortization	(974,374)	(1,151,677)	(1,230,010)
Balance - End of Year	$ 4,755,675	$ 5,601,656	$ 6,644,504

NOTE 7 - OTHER INTANGIBLE ASS_5

NOTE 7 - OTHER INTANGIBLE ASSETS - Forward Looking Schedule of Other Intangible Assets - (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
2020	$ 771,830
2021	381,860
2022	380,470
2023	383,929
2024	375,561
Thereafter	2,462,025
Other intangible assets - net	4,755,675	$ 5,601,656
Patents and Copyrights
2020	191,353
2021	191,860
2022	190,470
2023	193,929
2024	185,561
Thereafter	815,358
Other intangible assets - net	1,768,531
Non-competition
2020	390,477
2021
2022
2023
2024
Thereafter
Other intangible assets - net	390,477
Customer Relationships
2020	190,000
2021	190,000
2022	190,000
2023	190,000
2024	190,000
Thereafter	1,646,667
Other intangible assets - net	$ 2,596,667

NOTE 9 - CONTROLLING AND NONC_3

NOTE 9 - CONTROLLING AND NONCONTROLLING INTERESTS - HDM Members Equity (Details) - Health Diagnostics Management LLC (HDM) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Class A Members
Opening Members Equity	$ 3,559,182	$ 5,472,799	$ 8,396,575
Share of Net Income	5,196,543	4,221,383	4,058,177
Distributions	(6,600,000)	(6,135,000)	(6,981,953)
Ending Members Equity	2,155,725	3,559,182	5,472,799
Class B Members
Opening Members Equity	31,775,922	27,988,982	23,314,842
Share of Net Income	20,167,864	18,101,940	16,947,624
Distributions	(15,400,000)	(14,315,000)	(12,273,484)
Ending Members Equity	$ 36,543,786	$ 31,775,922	$ 27,988,982

NOTE 10 - LONG-TERM DEBT, NOT_3

NOTE 10 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES Long-Term Debt, Notes Payable And Capital Leases - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Long Term Debt, Notes Payable and Capital Leases	$ 313,642	$ 344,367
Current portion of Long Term Debt, Notes Payable and Capital Leases	40,530	38,332
Long Term Debt, Notes Payable and Capital Leases less Current Portion	$ 273,112	306,035
Long Term Note 1
Long Term Debt, Notes Payable and Capital Leases Description	Note payable requiring monthly payments of interest at a rate of 7% until May 2009 followed by 240 monthly payments of $4,472 through October 2026. The loan is collateralized by a building with a net book value of $481,666 as of June 30, 2019.
Long Term Debt, Notes Payable and Capital Leases	$ 306,056	336,781
Long Term Note 2
Long Term Debt, Notes Payable and Capital Leases Description	The revolving credit note was extended to August 2020. The Company can prepay the loan in whole or part in multiples of $100,000 at any time without penalty. The note bears interest at a rate of 5.25% per annum and is payable monthly. The loan is collateralized by substantially all of the Company's assets. The loan also contains certain financial covenants that must be met on a periodic basis. The note was paid in full September 2, 2014. The Company still has the ability to draw down on the line.
Long Term Debt, Notes Payable and Capital Leases
Long Term Note 3
Long Term Debt, Notes Payable and Capital Leases Description	Other (including capital leases for property and equipment)
Long Term Debt, Notes Payable and Capital Leases	$ 7,586	$ 7,586

NOTE 10 - LONG-TERM DEBT, NOT_4

NOTE 10 - LONG-TERM DEBT, NOTES PAYABLE & CAPITAL LEASES - Maturities Of Long-Term Debt Over 5 Years - (Details)	Jun. 30, 2018USD ($)
Debt Disclosure [Abstract]
2020	$ 40,530
2021	35,416
2022	38,013
2023	40,820
2024	43,767
Thereafter	115,096
Long-Term Debt Over Five Years and Thereafter	$ 313,642

NOTE 11 - INCOME TAXES - Compon

NOTE 11 - INCOME TAXES - Components Of Current Benefit For Income Taxes - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Current: Federal		$ 185,000	$ 250,000
Current: State	$ 250,000	265,000	357,235
Subtotal Current Federal and State	250,000	450,000	607,235
Federal Deferred taxes	1,685,299	(4,132,590)	(4,552,702)
State Deferred taxes	70,221	(787,160)	(416,967)
AMT Credit		(1,200,000)
Subtotal Deferred Federal and State Taxes	1,755,520	(6,119,750)	(4,969,669)
Provision (Benefit) for Income Taxes - Net	$ 2,005,520	$ (5,669,750)	$ (4,362,434)

NOTE 11 - INCOME TAXES - Reconc

NOTE 11 - INCOME TAXES - Reconciliation of Federal Statutory Income Tax Rate (Details)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Note 11 - Income Taxes - Reconciliation Of Federal Statutory Income Tax Rate
Taxes at federal statutory rate	21.00%	27.70%	35.00%
State and local income taxes (benefit), net of federal benefit	4.00%	4.00%	4.00%
Non controlling interest	(5.80%)	(6.80%)	(8.20%)
Permanent differences (taxes)	(3.50%)	0.10%	0.10%
Tax Cuts and Jobs Act Rate Change	0.00%	(26.90%)	0.00%
Decrease in the valuation allowance	(2.60%)	(18.50%)	(56.00%)
AMT Credits	0.00%	(6.40%)	0.00%
Other	(4.20%)	(1.80%)	2.00%
Effective income tax rate	8.90%	(28.60%)	(22.60%)

NOTE 11 - INCOME TAXES - Signif

NOTE 11 - INCOME TAXES - Significant Components Of Company's Deferred Tax Assets And Liabilities - (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Deferred Tax Assets:
Allowance for doubtful accounts	$ 3,011,480	$ 3,262,504
Non Deductible Accruals	861,345	752,595
Net operating carryforwards	16,448,054	20,665,597
Tax credits	4,601,801	4,330,769
Inventory	65,081	55,514
Property and equipment and depreciation	192,133	213,781
Deferred Tax Assets - gross	25,179,894	29,280,760
Valuation allowance	(4,242,147)	(6,591,749)
Total Deferred tax assets	20,937,747	22,689,011
Deferred tax liabilities:
Intangibles	(243,267)	(239,011)
Total deferred tax liabilities	(243,267)	(239,011)
Net Deferred Tax Asset	$ 20,694,480	$ 22,450,000

NOTE 12 - OTHER CURRENT LIABI_3

NOTE 12 - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Payables and Accruals [Abstract]
Accrued salaries, commissions and payroll taxes	$ 3,897,833	$ 3,438,087
Litigation accruals	145,029	145,029
Sales tax payable	1,671,488	2,092,403
Legal and other professional fees	125,567	119,262
Accounting fees	105,000	125,000
Self-funded health insurance reserve	67,825	79,129
Accrued Interest and penalty	1,054,134	1,497,429
Other	510,540	681,656
Other current liabilities	$ 7,577,416	$ 8,177,995

NOTE 13 - COMMITMENTS AND CON_3

NOTE 13 - COMMITMENTS AND CONTINGENCIES - Future Minimum Operating Lease Commitments - (Details)	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Facilities And Equipment (Operating Lease) Due in 2020	$ 4,655,396
Facilities And Equipment (Operating Lease) Due in 2021	4,323,037
Facilities And Equipment (Operating Lease) Due in 2022	3,396,273
Facilities And Equipment (Operating Lease) Due in 2023	2,778,617
Facilities And Equipment (Operating Lease) Due in 2024	2,350,193
Facilities And Equipment (Operating Lease) Due Thereafter	5,081,636
Total minimum obligations	$ 22,585,152

NOTE 16 - SEGMENT AND RELATED_3

NOTE 16 - SEGMENT AND RELATED INFORMATION - Sumarized Segments - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Total Revenues - Net	$ 87,192,887	$ 81,515,994	$ 78,036,586
Intersegment net revenues	907,084	901,250	1,200,000
Income (Loss) from operations	22,134,192	19,684,211	19,096,080
Depreciation and amortization	3,836,491	3,899,851	3,533,564
compensatory element of stock issuances	1,990,380	1,954,744	2,397,276
Total identifiable assets	130,263,901	118,310,945	98,762,566
Capital expenditures	3,483,849	2,886,777	3,006,314
Manufacturing And Servicing Of Medical Equipment
Total Revenues - Net	10,013,394	9,837,269	11,219,188
Intersegment net revenues	907,084	901,250	1,200,000
Income (Loss) from operations	(3,419,944)	(2,982,778)	(2,292,312)
Depreciation and amortization	370,001	353,307	324,550
compensatory element of stock issuances	1,990,380	1,954,744	2,397,276
Total identifiable assets	25,065,808	32,364,298	29,103,809
Capital expenditures	746,768	346,608	212,983
Management of Diagnostic Imaging Centers
Total Revenues - Net	77,179,493	71,678,725	66,817,398
Income (Loss) from operations	25,554,136	22,666,989	21,388,392
Depreciation and amortization	3,466,490	3,546,544	3,209,014
Total identifiable assets	105,198,093	85,946,647	69,658,676
Capital expenditures	$ 2,737,081	$ 2,540,169	$ 2,793,331

NOTE 16 - SEGMENT AND RELATED_4

NOTE 16 - SEGMENT AND RELATED INFORMATION - Foreign Product Sales - (Details)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Foreign Product Sales	530.00%	4150.00%	5590.00%
United Arab Emerites
Foreign Product Sales		710.00%	4540.00%
Canada
Foreign Product Sales	30.00%
England
Foreign Product Sales	30.00%	2990.00%	480.00%
Germany
Foreign Product Sales		450.00%
Puerto Rico
Foreign Product Sales	470.00%		570.00%

NOTE 16 - SEGMENT AND RELATED_5

NOTE 16 - SEGMENT AND RELATED INFORMATION - Foreign Service and Repair Fees - (Details)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Foreign Service and Repair fees	5.90%	5.00%	4.60%
Puerto Rico
Foreign Service and Repair fees	1.60%	1.50%	1.20%
Switzerland
Foreign Service and Repair fees	0.30%	0.20%	0.20%
Germany
Foreign Service and Repair fees	1.40%	1.30%	1.40%
England
Foreign Service and Repair fees	0.60%	0.60%	0.50%
United Arab Emerites
Foreign Service and Repair fees	0.30%	0.30%
Canada
Foreign Service and Repair fees	0.40%		0.10%
Greece
Foreign Service and Repair fees	0.30%	0.20%	0.20%
Australia
Foreign Service and Repair fees	1.00%	0.90%	1.00%

NOTE 17 - ALLOWANCE FOR DOUBT_3

NOTE 17 - ALLOWANCE FOR DOUBTFUL ACCOUNTS - Allowance For Doubtful Accounts (Details) (USD $) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Receivables from equipment sales and service contracts
Beginning Balance	$ 190,244	$ 190,244	$ 284,279
Deductions			94,035
Ending Balance	190,244	190,244	190,244
Management fee receivable
Beginning Balance	10,983,022	12,859,750	13,553,005
Additions (Included in provision for bad debts)	(1,578,078)	(1,744,064)	(104,424)
Deductions		132,664	588,831
Ending Balance	9,404,944	10,983,022	12,859,750
Management fee receivable from related medical practices
Beginning Balance	1,711,385	582,001	392,505
Additions (Included in provision for bad debts)	599,346	1,129,384	582,001
Deductions			392,505
Ending Balance	2,310,731	1,711,385	582,001
Medical receivables
Beginning Balance	22,727,698	19,853,318	17,451,782
Additions (Included in provision for bad debts)		17,896,528	16,171,434
Deductions	$ 22,727,698	15,022,148	12,547,160
Ending Balance		$ 22,727,698	$ 19,853,318

NOTE 18 - QUARTERLY FINANCIAL_3

NOTE 18 - QUARTERLY FINANCIAL DATA (UNAUDITED) - Unaudited Quarterly Financial Tables- (Details) - USD ($)	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Total Revenues - Net									$ 87,192,887	$ 81,515,994	$ 78,036,586
Total Costs and Expenses									65,058,695	61,831,783	58,940,506
Net Income									20,513,674	25,452,185	$ 23,678,798
Quarterly Financial Data [Member]
Total Revenues - Net	$ 22,484,000	$ 22,779,000	$ 21,225,000	$ 20,705,000	$ 21,035,000	$ 20,979,000	$ 20,168,000	$ 19,334,000	87,193,000	81,516,000
Total Costs and Expenses	18,480,000	16,171,000	15,245,000	15,163,000	16,348,000	16,577,000	14,358,000	14,549,000	65,059,000	61,832,000
Net Income	$ 2,665,000	$ 5,201,000	$ 4,864,000	$ 4,492,000	$ 11,349,000	$ 4,262,000	$ 5,240,000	$ 4,601,000	$ 17,222,000	$ 25,452,000
Basic Net Income Per Common Share Available to Common Stockholders	$ 0.20	$ 0.57	$ 0.52	$ 0.49	$ 1.47	$ 0.52	$ 0.62	$ 0.55	$ 1.78	$ 3.16
Diluted Net Income Per Common Share Available to Common Stockholders	$ 0.19	$ 0.56	$ 0.51	$ 0.48	$ 1.44	$ 0.51	$ 0.61	$ 0.54	$ 1.74	$ 3.10

NOTE 19 - BUSINESS COMBINATIO_3

NOTE 19 - BUSINESS COMBINATIONS - Acquisition - Turnkey Equipment (Details) - Turnkey Equipment Management of Great Neck, LLC	Jun. 15, 2017USD ($)
Cash Paid	$ 1,312,769
Security deposit	23,775
Total consideration	1,336,544
Net assets at Fair Value	731,582
Goodwill from Acquisition of Business	$ 604,962

NOTE 19 - BUSINESS COMBINATIO_4

NOTE 19 - BUSINESS COMBINATIONS - Acquisition - Radwell Leasing (Details) - Radwell Leasing, LLC & Radwell LLC	Mar. 20, 2017USD ($)
Diagnostic equipment	$ 544,375
Leasehold Improvements	126,237
Total Net Assets Acquired	670,612
Stock issued as consideration	791,210
Less: Cash Received	(120,598)
Total consideration	$ 670,612

NOTE 20 - REVISION - (Details)

NOTE 20 - REVISION - (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Cash and cash equivalents	$ 13,882,013	$ 9,780	$ 19,633,742	$ 10,139,621	$ 8,528,309
Short-term investments	$ 15,094,816	15,000
Previously Reported [Member]
Cash and cash equivalents		24,780
Short-term investments		0
Restatement Adjustment [Member]
Cash and cash equivalents		(15,000)
Short-term investments		$ 15,000

NOTE 20 - REVISION (Details)

NOTE 20 - REVISION (Details) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Cash Flows from Investing Activities	$ (18,157)	$ (18,578,665)	$ (2,945,051)	$ (4,319,083)
Cash and cash equivalents - end of period	9,780
Previously Reported [Member]
Cash Flows from Investing Activities	(3,157)
Cash and cash equivalents - end of period	24,780
Restatement Adjustment [Member]
Cash Flows from Investing Activities	(15,000)
Cash and cash equivalents - end of period	$ (15,000)

NOTE 1 - DESCRIPTION OF BUSIN_2

NOTE 1 - DESCRIPTION OF BUSINESS, LIQUIDITY AND CAPITAL RESOURCES (Details Narrative)	Jul. 02, 2015	May 01, 2012
Note 1 - Description Of Business Liquidity And Capital Resources
Contribution percent of its assets by Imperial (which were utilized in the business of Health Management Corporation of America) to HDM	100.00%
The ownership interest of Imperial Management Services after reorganization of newly expanded HDM (percent).	24.20%
The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM (percent).	45.80%
The ownership interest of the original investors of HDM after reorganization of newly expanded HDM (percent).	30.00%
Percent of management of diagnostic imaging centers business segment being conducted by HDM.	100.00%
Contribution by HMCA of all its assets and liabilities to Imperial Management Services, LLC (Imperial)		100.00%

NOTE 2 - SUMMARY OF SIGNIFICA_7

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Jun. 30, 2019USD ($)shares	Jun. 30, 2018USD ($)shares	Jun. 30, 2017USD ($)shares	Jun. 30, 2020USD ($)
Maintenance and Repair Expenses for Property and Equipment	$ 1,557,000	$ 1,451,000	$ 1,116,000
Management Agreements with Company - Total Medical Practices	22
Management Agreements with Company - Related Medical Practices	3
Management Agreements with Company - Located in New York State	19
Advertising Costs	$ 538,000	607,000	531,000
Shipping and Handling Expense	$ 13,695	$ 9,370	$ 8,224
Number of shares added to diluted EPS upon conversion of Class C Common | shares	127,504	127,504	127,504
Cash on Deposit in Bank in excess of federally insured limits	$ 11,842,000
Federally insured limit (FDIC)	$ 250,000
Net revenues from related parties as a percentage of consolidated net revenues	11.00%	11.00%	11.00%
Net management fee receivables from the related medical practices as a percentage of the consolidated accounts receivable	13.00%	12.00%	13.00%
Length of straight line basis for the amortization of customer relationships	20 years
Allowance for doubtful accounts for medical receivables-net	$ 22,727,698
Estimated operating lease liabilities and related right-of-use assets				$ 18,800,000
Diagnostic Imaging Facility
Contractual fees per month for services rendered minimum	54,000
Contractual fees per month for services rendered maximum	$ 481,000

NOTE 3 - ACCOUNTS RECEIVABLE,_4

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Note 3 - Accounts Receivable Medical Receivable And Management And Other Fees Receivable -
Percentage of PC's net revenue derived from no-fault and personal injury protection claims	67.00%	65.00%	62.00%
Percentage of consolidated net revenue from management fees charged to related party medical practices	11.00%	11.00%	11.00%

NOTE 6 - PROPERTY AND EQUIPME_4

NOTE 6 - PROPERTY AND EQUIPMENT- (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Property, Plant and Equipment [Member]
Depreciation and amortization of property and equipment	$ 2,862,117	$ 2,748,174	$ 2,303,554

NOTE 7 - OTHER INTANGIBLE ASS_6

NOTE 7 - OTHER INTANGIBLE ASSETS - (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Weighted average amortization period (years)	11 years 37 days
Patents and Copyrights
Amortization other intangible assets	$ 198,660	$ 202,630	$ 194,296
Capitalized software development costs
Amortization other intangible assets		173,333	260,000
Non-competition
Amortization other intangible assets	585,714	585,714	585,714
Customer Relationships
Amortization other intangible assets	$ 190,000	$ 190,000	$ 190,000

NOTE 8 - CAPITAL STOCK - (Detai

NOTE 8 - CAPITAL STOCK - (Details Narrative) - shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Aug. 10, 2010	Apr. 23, 2010
Shares reserved for 2010 Stock Bonus Plan					2,000,000
Shares Registered under Form S-8 for 2010 Stock Bonus Plan				2,000,000
Common Stock available under 2010 Stock Bonus Plan	645,905
Shares issued under 2010 Stock Bonus Plan	69,971	0	193,461
Common Shares
Dividends Payable Nature	Cash dividends payable on the common stock shall, in all cases, be on a per share basis, one hundred twenty percent (120%) of the cash dividend payable on shares of Class B common stock and three hundred sixty percent (360%) of the cash dividend payable on a share of Class C common stock.
Terms of Conversion	Class C common stock is convertible into shares of common stock on a three-for-one basis.
Votes Per Share	The Common stock has 1 vote per share.
Class B Members
Terms of Conversion	Class B common stock is convertible into shares of common stock on a one-for-one basis.
Shares Outstanding	There were 146 shares outstanding at June 30, 2019, 2018, and 2017, respectively.
Votes Per Share	The Class B common stock has 10 votes per share.
Class C Common Stock
Dividends Payable Nature	Although having greater voting power, each share of Class C common stock has only one-third of the rights of a share of Class B common stock to dividends and distributions.
Terms of Conversion	On April 3, 1995, the stockholders ratified a proposal creating a new Class C common stock and authorized the exchange offering of three shares of Class C common stock for each share of the Company's outstanding Class B common stock. The Class C common stock was offered on a three-for-one basis to the holders of the Class B common stock.
Votes Per Share	The Class C common stock has 25 votes per share.
Class A Non Voting Preferred Stock
Dividends Payable Nature	On April 3, 1995, the stockholders ratified a proposal consisting of the creation of a new class of Class A non-voting preferred stock with special dividend rights and the declaration of a stock dividend on the Company's common stock consisting of one share of Class A non-voting preferred stock for every five shares of common stock. The stock dividend was payable to holders of common stock on October 20, 1995. The Class A non-voting preferred stock is entitled to a special dividend equal to 3-1/4% of first $10 million, 4-1/2% of next $20 million and 5-1/2% on amounts in excess of $30 million of the amount of any cash awards or settlements received by the Company in connection with the enforcement of five of the Company's patents in its patent lawsuits, less the revised special dividend payable on the common stock with respect to one of the Company's patents. The Class A non-voting preferred stock participates on an equal per share basis with the common stock in any dividends declared and ranks equally with the common stock on distribution rights, liquidation rights and other rights and preferences (other than the voting rights).
Shares Outstanding	Class A non-voting preferred stock issued pursuant to such stock dividend approximates 313,000 shares.
Votes Per Share	The Class A non-voting preferred stock has no voting rights.

NOTE 9 - CONTROLLING AND NONC_4

NOTE 9 - CONTROLLING AND NONCONTROLLING INTERESTS - (Details Narrative)	Jan. 08, 2015USD ($)	Mar. 05, 2013USD ($)	Feb. 13, 2013USD ($)
Class B Member | Health Diagnostics Management LLC (HDM)
Health Diagnostics Management (HDM) Class B Members ownership interest			50.50%
Controlling Interest acquired by Company of Health Diagnostics Management, LLC, (HDM)			50.50%
Health Diagnostics Management (HDM) Class B (Company) Members contribution			$ 20,200,000
Class A Member | Health Diagnostics Management LLC (HDM)
Health Diagnostics Management (HDM) Class B Members ownership interest	60.40%
Health Diagnostics Management (HDM) Class A Members ownership interest			49.50%
Health Diagnostics Management (HDM) Class A (Outside Investors) Members contribution			$ 19,800,000
Company purchase price for 20% ownership in Health Diagnostic Management, LLC ($)	$ 4,971,094
Health Diagnostics Management LLC (HDM)
Health Diagnostics Management (HDM) purchase of Stand-Up MRI Centers from Health Diagnostics, LLC (HD)		12
Health Diagnostics Management (HDM) purchase of Other MRI Centers from Health Diagnostics, LLC (HD)		2
Total Cost of Health Diagnostics Management (HDM) purchase of the MRI Centers from Health Diagnostics, LLC (HD)		$ 35,900,000
Consideration to Outside Investors Regarding Health Diagnostics Management (HDM) purchase of the MRI Centers from Health Diagnostics, LLC (HD)		1,500,000
Consideration For Non-Competition and Consulting Agreements Regarding Health Diagnostics Management (HDM) purchase of the MRI Centers from Health Diagnostics, LLC (HD)		$ 4,100,000

NOTE 11 - INCOME TAXES - (Detai

NOTE 11 - INCOME TAXES - (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2020
Note 11 - Income Taxes -
Total Deferred tax assets	$ 20,937,747	$ 22,689,011
Deferred Tax Liability	243,267
Net Operating Loss (NOL) Carryforwards Available to Offset Future Taxable Income	65,792,000
Reduction in valuation allowance	$ 2,350,000	27,600,000
Revalued deferred tax assets		$ 16,000,000
Fonar Corporation statutory income tax rate	21.00%	27.70%
Research and Development Tax Credit Carryforwards	$ 4,602,000
Valuation reserve for anticipated unused tax credit caryforwards	3,902,000
Alternate Minimum Tax Credits		$ 1,200,000
First installment			$ 600,000
NY State Tax Credit Carryforwards	$ 250,000

NOTE 13 - COMMITMENTS AND CON_4

NOTE 13 - COMMITMENTS AND CONTINGENCIES - (Details Narrative) - USD ($)	12 Months Ended			120 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2028
Rent Expense	$ 4,688,000	$ 4,762,000	$ 4,505,000
Property Tax Abatement from Suffolk County IDA (dollars)				$ 440,000
Property Tax Abatement from Suffolk County IDA (%)				50.00%
Employer Contributions to 401(k) Plan	0	0	$ 0
Stipulation agreement with creditors	142,299
Average Monthly Payment for Stipulation Agreements	15,859
Recorded sales tax obligations - principal	1,671,000
Recorded sales tax obligations - interest and penalties	1,054,000
Reserve for Self-Funded Health Insurance Program	68,000	$ 79,000
Stop-Loss Umbrella Policy with 3rd Pary Insurer to Limit Maximum Potential Liability for individual Claims	$ 100,000
2000 Employee Stock Purchase Plan
2000 Employee Stock Purchase Plan (ESPP)	The stockholders of the Company approved the 2000 Employee Stock Purchase Plan (""""ESPP"""") at the Company's annual stockholders' meeting in April 2000. The ESPP provides for eligible employees to acquire common stock of the Company at a discount, not to exceed 15%. This plan has not been put into effect as of June 30, 2019.
Matt Malek Madison
Details of Case	Matt Malek Madison v. Fonar Corporation, United States District Court, Northern District of California, was commenced by plaintiff on August 27, 2007 to recover a down payment for a scanner in the amount of $300,000, with interest. The plaintiff sought costs of suit and attorney's fees as well. The Company answered the complaint and sued the plaintiff for breach of contract in the amount of $450,000. Although down payments are usually expressly non-refundable in the Company's quotations and agreements, in this case, the quotation contemplated the sale of four scanners, and provided that the deposit would be refundable with interest, if the customer were unable to find suitable locations in the San Francisco Bay area. The issue was whether the customer made a good faith effort to find locations; the Company's position was that the customer did not. The case went to trial before a judge; the parties submitted post-trial briefs, and judgment was awarded to the plaintiff. The Company appealed the trial court’s decision, but on January 31, 2012, the U.S. Court of Appeals for the 9th Circuit affirmed the lower court's decision awarding the plaintiff the $300,000 deposit with prejudgment interest from July 1, 2006. The Company sought to have the Court of Appeals reconsider the decision en banc, (by all or a larger number of the judges on the Circuit Court of Appeals), but this was not granted. During October 2016, the Company settled with the plaintiff for $300,000.
Settlement of Case (value)	$ 300,000

NOTE 14 - SUPPLEMENTAL CASH F_2

NOTE 14 - SUPPLEMENTAL CASH FLOW INFORMATION - (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Note 14 - Supplemental Cash Flow Information -
Interest paid	$ 165,172	$ 44,767	$ 162,022
Income taxes paid	304,575	$ 345,000	739,889
Issuance of stock for goods and services, Value	$ 1,954,744		$ 2,239,292
Issuance of stock for goods and services, Shares	69,971		106,600

NOTE 15 - RELATED PARTY PRACTIC

NOTE 15 - RELATED PARTY PRACTICES - (Details Narrative)	12 Months Ended
	Jun. 30, 2019
A Billing Company
Related Party Transaction, Description of Transaction	The CEO and President of the Company is a minority owner of a billing company, which performs billing and collection services with respect to No-Fault and Workers’ Compensation claims of the Company’s clients. The monthly fee charged to the Company is $85,000. On June 1, 2017, the Company also entered into a one year renewable agreement to provide IT services to the billing company for a monthly fee of $23,884. The agreement was renewed on June 1, 2019 for another year.
Bensonhurst MRI Limited Partnership
Related Party Transaction, Description of Transaction	Bensonhurst MRI Limited Partnership, in which the CEO and President of the Company holds an interest, is party to an agreement with the Company for the service and maintenance of its Upright MRI Scanner for a price of $110,000 per annum.
LimitedLiabilityCompany
Related Party Transaction, Description of Transaction	A limited liability company of which the CEO and President of the Company is an owner also had a 1.375% interest in Yonkers Diagnostic Management, LLC, a 4.5% interest in Turnkey Services of New York, LLC and a 4.3% interest in TK2 Equipment Management, LLC. Entities in which the Executive Vice President and COO and his family had an interest had a 0.75% in Yonkers and a 5.9% in TK2 Equipment Management . The Company acquired these entities, or the portion thereof not already owned by the Company, through a series of merger transactions for $1,780,000 in the case of Yonkers, $1,147,715 in the case of Turnkey Services and $3,075,852 in the case of TK2 Equipment Management
Company_1
Related Party Transaction, Description of Transaction	A company of which the CEO and President of the Company is an owner and a company in which the Executive Vice President and COO has an interest also hold a 1.7% and 2.8% interest, respectively, in Turnkey Management of Great Neck, LLC, an entity for which the Company performed management services. The Company acquired this through a merger transaction for $1,312,766.

NOTE 16 - SEGMENT AND RELATED_6

NOTE 16 - SEGMENT AND RELATED INFORMATION - (Details Narrative)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Note 16 - Segment And Related Information -
Export Sales of medical equipment	5.30%	41.50%	55.90%
Foreign Revenues of service and repair of medical equipment	5.90%	5.00%	4.60%

NOTE 19 - BUSINESS COMBINATIO_5

NOTE 19 - BUSINESS COMBINATIONS - (Details Narrative)	Jun. 15, 2017	Mar. 20, 2017
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net [Abstract]
Purchase % of equity in Turnkey Services of New York, LLC	100.00%
Purchase % of equity in Radwell Leasing LLC and Radwell LLC.		100.00%

NOTE 21 - SUBSEQUENT EVENTS - (

NOTE 21 - SUBSEQUENT EVENTS - (Details Narrative)	2 Months Ended
	Sep. 13, 2019USD ($)shares
Note 21 - Subsequent Events -
Shares of common stock issued in settlement of liabilities (Shares). | shares	89,981
Value of Shares Issued in Settlement of Liabilities (Value) | $	$ 2,000,000